Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Feb. 29, 2024 | Jun. 30, 2023 | |
Document Information [Line Items] | |||
Entity Central Index Key | 0000738214 | ||
Entity Registrant Name | AEMETIS, INC | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --12-31 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2023 | ||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2023 | ||
Document Transition Report | false | ||
Entity File Number | 001-36475 | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 26-1407544 | ||
Entity Address, Address Line One | 20400 Stevens Creek Blvd., Suite 700 | ||
Entity Address, City or Town | Cupertino | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 95014 | ||
City Area Code | 408 | ||
Local Phone Number | 213-0940 | ||
Title of 12(b) Security | Common Stock, $0.001 par value | ||
Trading Symbol | AMTX | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Document Financial Statement Error Correction [Flag] | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 253,200,000 | ||
Entity Common Stock, Shares Outstanding | 42,608,698 | ||
Auditor Firm ID | 49 | ||
Auditor Name | RSM US LLP | ||
Auditor Location | Des Moines, Iowa |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 2,667 | $ 4,313 |
Accounts receivable | 8,633 | 1,264 |
Inventories, net of allowance for excess and obsolete inventory of $1,040 as of December 31, 2023 and 2022 | 18,291 | 4,658 |
Prepaid expenses | 3,347 | 4,248 |
Other current assets | 3,462 | 3,653 |
Total current assets | 36,400 | 18,136 |
Property, plant and equipment, net | 195,108 | 180,441 |
Operating lease right-of-use assets | 2,056 | 2,449 |
Other assets | 9,842 | 6,088 |
Total assets | 243,406 | 207,114 |
Current liabilities: | ||
Accounts payable | 32,132 | 26,168 |
Current portion of long term debt | 13,585 | 12,465 |
Short term borrowings | 23,443 | 36,754 |
Current portion of operating lease liability | 406 | 338 |
Other current liabilities | 10,302 | 8,474 |
Total current liabilities | 84,389 | 88,281 |
Long term liabilities: | ||
Senior secured notes and revolving notes | 176,476 | 155,843 |
EB-5 notes | 29,500 | 29,500 |
Other long term debt | 51,717 | 11,678 |
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent | 113,200 | 116,000 |
Operating lease liability | 1,783 | 2,189 |
Other long term liabilities | 3,329 | 5,477 |
Total long term liabilities | 375,994 | 320,687 |
Stockholders' deficit: | ||
Common stock, $0.001 par value; 80,000 authorized; 40,966 and 35,869 shares issued and outstanding each period, respectively | 41 | 36 |
Additional paid-in capital | 264,058 | 232,546 |
Accumulated deficit | (475,405) | (428,985) |
Accumulated other comprehensive loss | (5,671) | (5,452) |
Total stockholders' deficit | (216,977) | (201,854) |
Total liabilities and stockholders' deficit | 243,406 | 207,114 |
Series B Convertible Preferred Stock [Member] | ||
Stockholders' deficit: | ||
Series B convertible preferred stock, $0.001 par value; 7,235 authorized; 0 and 1,270 shares issued and outstanding each period, respectively (aggregate liquidation preference of $0 and $3,810 respectively) | 0 | 1 |
Convertible Series B Preferred Stock Subject to Mandatory Redemption [Member] | ||
Current liabilities: | ||
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current | 4,521 | 4,082 |
Convertible Series A Preferred Stock Subject to Mandatory Redemption [Member] | ||
Long term liabilities: | ||
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent | $ 113,189 | $ 116,000 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Cash and cash equivalents | $ 2,667 | $ 4,313 |
Accounts receivable | 8,633 | 1,264 |
Inventory Valuation Reserves | 1,040 | 1,040 |
Prepaid expenses | 3,347 | 4,248 |
Other current assets | 3,462 | 3,653 |
Property, plant and equipment, net | 195,108 | 180,441 |
Operating lease right-of-use assets | 2,056 | 2,449 |
Other assets | 9,842 | 6,088 |
Accounts payable | 32,132 | 26,168 |
Current portion of long term debt | 13,585 | 12,465 |
Short term borrowings | 23,443 | 36,754 |
Current portion of operating lease liability | 406 | 338 |
Other current liabilities | 10,302 | 8,474 |
Other long term debt | 51,717 | 11,678 |
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent | 113,200 | 116,000 |
Operating lease liability | $ 1,783 | $ 2,189 |
Series B Preferred Stock, Authorized (in shares) | 65,000 | |
Series B Preferred Stock, Shares Issued (in shares) | 0 | 1,270 |
Common Stock, Par Value (in dollars per share) | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized (in shares) | 80,000 | 80,000 |
Common Stock, Shares Issued (in shares) | 40,966 | 35,869 |
Common Stock, Shares Outstanding (in shares) | 40,966 | 35,869 |
Series B Convertible Preferred Stock [Member] | ||
Series B Preferred Stock, Par Value (in dollars per share) | $ 0.001 | $ 0.001 |
Series B Preferred Stock, Authorized (in shares) | 7,235 | 7,235 |
Series B Preferred Stock, Shares Issued (in shares) | 0 | 1,270 |
Series B Preferred Stock, Shares Outstanding (in shares) | 0 | 1,270 |
Aggregate Liquidation Preference | $ 0 | $ 3,810 |
Convertible Series A Preferred Stock Subject to Mandatory Redemption [Member] | ||
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent | 113,189 | 116,000 |
Variable Interest Entity, Primary Beneficiary [Member] | ||
Cash and cash equivalents | 1,093 | 165 |
Accounts receivable | 55 | 165 |
Prepaid expenses | 1,438 | 858 |
Other current assets | 289 | 725 |
Property, plant and equipment, net | 81,966 | 71,633 |
Operating lease right-of-use assets | 145 | 224 |
Other assets | 4,881 | 3,458 |
Accounts payable | 3,815 | 9,192 |
Current portion of long term debt | 190 | 0 |
Short term borrowings | 9 | 19,831 |
Current portion of operating lease liability | 48 | 41 |
Other current liabilities | 0 | 645 |
Other long term debt | 40,857 | 31 |
Operating lease liability | 67 | 115 |
Variable Interest Entity, Primary Beneficiary [Member] | Convertible Series A Preferred Stock Subject to Mandatory Redemption [Member] | ||
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent | $ 113,189 | $ 116,000 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenues | $ 186,717 | $ 256,513 |
Cost of goods sold | 184,700 | 262,048 |
Gross (loss) profit | 2,017 | (5,535) |
Research and development expenses | 152 | 180 |
Selling, general and administrative expenses | 39,266 | 28,686 |
Operating loss | (37,401) | (34,401) |
Other expense (income): | ||
Interest rate expense | 32,995 | 21,407 |
Debt related fees and amortization expense | 6,524 | 7,363 |
Accretion and other expenses of Series A preferred units | 25,313 | 9,888 |
Loss on debt extinguishment | 0 | 49,386 |
Gain on litigation | 0 | (1,400) |
Other income | (2,077) | (14,340) |
Loss before income taxes | (100,156) | (106,705) |
Income tax expense (benefit) | (53,736) | 1,053 |
Net loss | (46,420) | (107,758) |
Other comprehensive (loss) | ||
Foreign currency translation loss | (219) | (1,102) |
Comprehensive loss | $ (46,639) | $ (108,860) |
Net loss per common share | ||
Basic (in dollars per share) | $ (1.22) | $ (3.12) |
Diluted (in dollars per share) | $ (1.22) | $ (3.12) |
Weighted average shares outstanding | ||
Basic (in shares) | 38,061 | 34,585 |
Diluted (in shares) | 38,061 | 34,585 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating activities: | ||
Net loss | $ (46,420) | $ (107,758) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
Share-based compensation | 7,660 | 6,410 |
Depreciation | 6,933 | 5,535 |
Debt related fees and amortization expense | 6,524 | 7,363 |
Intangibles and other amortization expense | 72 | 46 |
Accretion and other expenses of Series A preferred units | 25,313 | 9,888 |
Warrants issued for working capital agreement | 409 | 0 |
Loss on asset disposals | 0 | 47 |
Loss on debt extinguishment | 0 | 49,386 |
Gain on litigation | 0 | (1,400) |
Loss on lease termination | 0 | 736 |
Deferred tax (benefit) expense | (750) | 832 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (7,422) | 294 |
Inventories | (13,843) | 360 |
Prepaid expenses | 1,838 | 1,777 |
Other assets | (2,016) | (3,941) |
Accounts payable | 13,726 | 2,183 |
Accrued interest expense and fees | 23,558 | 15,501 |
Other liabilities | (1,757) | (10,125) |
Net cash provided by (used in) operating activities | 13,825 | (22,866) |
Investing activities: | ||
Capital expenditures | (33,119) | (39,157) |
Grant proceeds received for capital expenditures | 9,432 | 7,851 |
Net cash used in investing activities | (23,687) | (31,306) |
Financing activities: | ||
Proceeds from borrowings | 75,482 | 69,356 |
Repayments of borrowings | (56,130) | (26,266) |
Lender debt renewal and waiver fee payments | (1,681) | (1,169) |
Payments on Series A preferred financing | (30,000) | 0 |
Payments on finance leases | (428) | (481) |
Proceeds from issuance of common stock in equity offering | 21,718 | 11,987 |
Proceeds from the exercise of stock options | 133 | 206 |
Net cash provided by financing activities | 9,094 | 53,633 |
Effect of exchange rate changes on cash and cash equivalents | 49 | (213) |
Net change in cash and cash equivalents for period | (719) | (752) |
Cash, cash equivalents, and restricted cash at beginning of period | 6,999 | 7,751 |
Cash, cash equivalents, and restricted cash at end of period | 6,280 | 6,999 |
Supplemental disclosures of cash flow information, cash paid: | ||
Cash paid for interest | 9,813 | 19,515 |
Income taxes paid | 20 | 10 |
Supplemental disclosures of cash flow information, non-cash transactions: | ||
Subordinated debt extension fees added to debt | 680 | 680 |
Debt fees added to revolving lines | 0 | 800 |
Fair value of warrants issued to subordinated debt holders | 1,278 | 1,939 |
Fair value of stock issued to a related party for guarantee fees | 0 | 2,012 |
Fair value of warrants issued to lender for debt issuance costs | 318 | 3,158 |
Fair value of stock issued to lender | 0 | 1,335 |
Lender debt extension, waiver, and other fees added to debt | 0 | 583 |
Capital expenditures in accounts payable | 7,900 | 15,411 |
Payment of debt added to revolving lines | 0 | 16,266 |
Operating lease liabilities arising from obtaining right of use assets | 0 | 306 |
Financing lease liabilities arising from obtaining right of use assets | 0 | 2,932 |
Capital expenditures purchased on financing | $ 0 | $ 290 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Total |
Balance (in shares) at Dec. 31, 2021 | 1,275 | 33,461 | ||||
Balance at Dec. 31, 2021 | $ 1 | $ 33 | $ 205,305 | $ (321,227) | $ (4,350) | $ (120,238) |
Issuance of common stock (in shares) | 0 | 1,885 | ||||
Issuance of common stock | $ 0 | $ 3 | 15,530 | 0 | 0 | 15,533 |
Series B conversion to common stock (in shares) | (5) | (1) | ||||
Series B conversion to common stock | $ 0 | $ 0 | 0 | 0 | 0 | 0 |
Series B conversion to common stock (in shares) | 5 | 1 | ||||
Stock options exercised (in shares) | 0 | 296 | ||||
Stock options exercised | $ 0 | $ 0 | 205 | 0 | 0 | 205 |
Stock-based compensation | $ 0 | $ 0 | 6,410 | 0 | 0 | 6,410 |
Issuance and exercise of warrants (in shares) | 0 | 226 | ||||
Issuance and exercise of warrants | $ 0 | $ 0 | 5,096 | 0 | 0 | 5,096 |
Foreign currency translation loss | 0 | 0 | 0 | 0 | (1,102) | (1,102) |
Net loss | $ 0 | $ 0 | 0 | (107,758) | 0 | (107,758) |
Series B conversion to common stock (in shares) | 5 | 1 | ||||
Balance (in shares) at Dec. 31, 2022 | 1,270 | 35,869 | ||||
Balance at Dec. 31, 2022 | $ 1 | $ 36 | 232,546 | (428,985) | (5,452) | (201,854) |
Issuance of common stock (in shares) | 0 | 4,499 | ||||
Issuance of common stock | $ 0 | $ 4 | 21,714 | 0 | 0 | 21,718 |
Series B conversion to common stock (in shares) | (1,270) | (127) | ||||
Series B conversion to common stock | $ (1) | $ 1 | 0 | 0 | 0 | 0 |
Series B conversion to common stock (in shares) | 1,270 | 127 | ||||
Stock options exercised (in shares) | 0 | 183 | ||||
Stock options exercised | $ 0 | $ 0 | 133 | 0 | 0 | 133 |
Stock-based compensation | $ 0 | $ 0 | 7,660 | 0 | 0 | 7,660 |
Issuance and exercise of warrants (in shares) | 0 | 288 | ||||
Issuance and exercise of warrants | $ 0 | $ 0 | 2,005 | 0 | 0 | 2,005 |
Foreign currency translation loss | 0 | 0 | 0 | 0 | (219) | (219) |
Net loss | $ 0 | $ 0 | 0 | (46,420) | 0 | (46,420) |
Series B conversion to common stock (in shares) | 1,270 | 127 | ||||
Balance (in shares) at Dec. 31, 2023 | 0 | 40,966 | ||||
Balance at Dec. 31, 2023 | $ 0 | $ 41 | $ 264,058 | $ (475,405) | $ (5,671) | $ (216,977) |
Note 1 - Nature of Activities a
Note 1 - Nature of Activities and Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Basis of Presentation and Significant Accounting Policies [Text Block] | 1. Nature of Activities ● Aemetis Americas, Inc., a Delaware corporation, and its subsidiary AE Biofuels, Inc., a Delaware corporation; ● Aemetis International, Inc., a Nevada corporation, and its subsidiary International Biofuels Ltd, a Mauritius corporation, and its subsidiary Universal Biofuels Private Limited, an India company; ● Aemetis Technologies, Inc., a Delaware corporation; ● Aemetis Biofuels, Inc., a Delaware corporation, and its subsidiary Energy Enzymes, Inc., a Delaware corporation; ● AE Advanced Fuels, Inc., a Delaware corporation, and its subsidiaries Aemetis Advanced Fuels Keyes, Inc., a Delaware corporation, Aemetis Facility Keyes, Inc., a Delaware corporation, and Aemetis Property Keyes, Inc., a Delaware corporation; ● Aemetis Advanced Fuels, Inc., a Nevada corporation; ● Aemetis Advanced Products Keyes, Inc., a Delaware corporation, and its subsidiaries Aemetis Properties Riverbank, Inc., a Delaware corporation, Aemetis Health Products, Inc., a Delaware corporation; and Aemetis Riverbank, Inc., a Delaware corporation, and its subsidiary Aemetis Advanced Products Riverbank, Inc., a Delaware corporation; ● Aemetis Advanced Biorefinery Keyes, Inc., a Delaware corporation; ● Aemetis Carbon Capture, Inc. a Nevada corporation; ● Aemetis Biogas LLC, a Delaware Limited Liability Company and its subsidiaries Aemetis Biogas Services LLC, a Delaware Limited Liability Company, and Aemetis Biogas Holdings LLC, a Delaware Limited Liability Company, and its subsidiaries Aemetis Biogas 1 2 3 4 5 6 7 8 ● Goodland Advanced Fuels, Inc., a Nevada corporation. Founded in 2006 three not Basis of Presentation and Consolidation. not All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates Revenue Recognition 606 California Ethanol: 2022 second 2023, second 2023, not Given the similarity of the individual sales transactions with J.D. Heiskell, we have assessed them as a portfolio of similar contracts. Prior to May 25, 2023, May 25, 2023, one During the last two December 2022, first second 2023 May 2023. The following table shows our sales in California Ethanol by product category: California Ethanol For the twelve months ended December 31, 2023 2022 Ethanol sales $ 78,403 $ 165,876 Wet distiller's grains sales 21,963 50,930 Other sales 3,702 11,388 $ 104,068 $ 228,194 California Dairy Renewable Natural Gas: December 31, 2023, seven 26 2023, seven "D3 D3 third 2023 first 2024. D3 Dairy Renewable Natural Gas For the twelve months ended December 31, 2023 2022 Molecule and RIN sales $ 5,455 $ 208 India Biodiesel: not one The following table shows our sales in India by product category: India Biodiesel For the twelve months ended December 31, 2023 2022 Biodiesel sales $ 74,503 $ 27,041 Other sales 2,691 1,070 $ 77,194 $ 28,111 Cost of Goods Sold January May 2023, Shipping and Handling Costs Research and Development. Cash, Cash Equivalents, and Restricted Cash three may not AB1 AB2 The following table reconciles cash, cash equivalents, and restricted cash reported in the Consolidated Balance Sheet to the total of the same such amounts shown in the statement of cash flows. As of December 31, 2023 December 31, 2022 Cash and cash equivalents $ 2,667 $ 4,313 Restricted cash included in other current assets 289 725 Restricted cash included in other assets 3,324 1,961 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 6,280 $ 6,999 Accounts Receivable. The Company sells all of its products to J.D. Heiskell under the J.D. Heiskell Purchasing Agreement. Our third may 30 The Company maintains an allowance for doubtful accounts for balances that appear to have specific collection issues and estimates an allowance for expected credit losses. The collection process is based on the age of the invoice and requires attempted contacts with the customer at specified intervals. If, after a specified number of days, the Company has been unsuccessful in its collection efforts, a bad debt allowance is recorded for the balance in question. Delinquent accounts receivables are charged against the allowance for doubtful accounts once un-collectability has been determined. The factors considered in reaching this determination are the apparent financial condition of the customer and the Company’s success in contacting and negotiating with the customer. If the financial condition of the Company’s customers were to deteriorate, additional allowances may Inventories first first Other current assets Variable Interest Entities. 1 2 not Property, Plant and Equipment. The Company evaluates the recoverability of long-lived assets with finite lives in accordance with ASC Subtopic 360 10 35 Property Plant and Equipment Subsequent Measurement, may not may not not December 31, 2023 2022 Grants Received. California Energy Commission Low-Carbon Fuel Production Program December 31, 2023 California Department of Food and Agriculture Dairy Digester Research and Development Grant 2 019, two second 2021. October 2020, six 2020 December 31, 2023 California Energy Commission Low Carbon Advanced Ethanol Grant Program. May 2019, not not not December 31, 2023 2022 U.S. Department of Food and Agriculture Forest Service Grant. December 31, 2023 California Energy Commission Grant for Solar Microgrid, DSC and Battery Backup System. 1.56 1.25MW/2.5MWh December 31, 2023 California Department of Forestry and Fire Protection Grant. May 2022. 2 100% December 31, 2023 California Department of Forestry and Fire Protection Grant. May 2022. December 31, 2023 U.S. Forest Service Community Wood Grant. May 2022. 3 no December 31, 2023 USDA Biofuel Producer Program Grant. second 2022, 19 California Energy Commission Grant for Mechanical Vapor Recompression System. December 31, 2023 PG&E A2313 February 2023, Pacific Gas and Electric SEM Manufacturer s Incentive Program. fourth 2022, Investment Tax Credits. third 2023, third 740 December 31, 2023. October 2023, Income Taxes 740 Income Taxes 740 not may not December 31, 2023 2022 The Company is subject to income tax audits by the respective tax authorities in all of the jurisdictions in which it operates. The determination of tax liabilities in each of these jurisdictions requires the interpretation and application of complex and sometimes uncertain tax laws and regulations. The recognition and measurement of current taxes payable or refundable and deferred tax assets and liabilities requires that the Company make certain estimates and judgments. Changes to these estimates or a change in judgment may In 2018, 1 2 Basic and Diluted Net Income (Loss) per Share. December 31, 2023 2022 The following table shows the number of potentially dilutive shares excluded from the diluted net loss per share calculation as of December 31, 2023 2022 As of December 31, 2023 December 31, 2022 Series B preferred (post split basis) - 127 Common stock options and warrants 6,056 5,050 Debt with conversion feature at $ 30 1,267 1,240 Total number of potentially dilutive shares excluded from the diluted net (loss) per share calculation 7,323 6,417 Comprehensive Loss. 220 Comprehensive Income not Foreign Currency Translation/Transactions. Fair Value of Financial Instruments. not 3 Share Based Compensation. ize share-based compensation expense in accordance with ASC 718 Stock Compensation, which requires the Company to recognize expenses related to the estimated fair value of the Company’s share-based compensation awards over the vesting period, adjusted to reflect only those shares that are expected to vest. Commitments and Contingencies. 450 Contingencies 450 one Convertible Instruments. Debt Issuance Costs. Troubled Debt Restructuring Accounting. Debt Modification Accounting 540 50 Debt Modification and Extinguishments 10 10 Recently Adopted Accounting Pronouncements In November 2023, 2023 07, 280 2023 07, 280 January 1, 2024, January 1, 2025. 2023 07 In December 2023, 2023 09, 740 January 1, 2025, 2023 09 There were no |
Note 2 - Inventories
Note 2 - Inventories | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | 2. Inventories consist of the following: As of December 31, 2023 December 31, 2022 Raw materials $ 9,907 $ 2,971 Work-in-progress 1,682 127 Finished goods 6,702 1,560 Total inventories $ 18,291 $ 4,658 As of December 31, 2023 December 31, 2022 of $58 thousand and $0.1 million |
Note 3 - Property, Plant and Eq
Note 3 - Property, Plant and Equipment | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | 3. Property, plant and equipment consist of the following: As of December 31, 2023 December 31, 2022 Land $ 7,345 $ 7,344 Plant and buildings 136,318 99,116 Furniture and fixtures 2,266 1,831 Machinery and equipment 14,982 15,209 Construction in progress 73,057 88,990 Property held for development 15,431 15,437 Finance lease right of use assets 2,889 3,045 Total gross property, plant & equipment 252,288 230,972 Less accumulated depreciation (57,180 ) (50,531 ) Total net property, plant & equipment $ 195,108 $ 180,441 Interest capitalized in property, plant, and equipme nt was $5.6 million and $11.1 million for the years ended December 31, 2023 2022 , respectively. Construction in progress includes costs for the biogas construction projects (dairy digesters and not Years Plant and buildings 20 - 30 Machinery and equipment 5 - 15 Furniture and fixtures 3 - 5 The Company recorded depreciation expense of approximat ely $6.9 million and $5.5 million respectively, for the years ended December 31, 2023 2022 . |
Note 4 - Debt
Note 4 - Debt | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 4. Debt consists of the notes from the Company’s senior lender, Third Eye Capital, acting as Agent for the Purchasers (Third Eye Capital), other working capital lenders and subordinated lenders as follows: December 31, 2023 December 31, 2022 Third Eye Capital term notes $ 7,159 $ 7,141 Third Eye Capital revolving credit facility 20,922 60,602 Third Eye Capital revolving notes Series B 54,412 - Third Eye Capital revenue participation term notes 12,011 11,963 Third Eye Capital acquisition term notes 26,655 26,578 Third Eye Capital Fuels Revolving Line 32,511 27,410 Third Eye Capital Carbon Revolving Line 23,486 22,710 Construction Loan 41,024 19,820 Cilion shareholder seller notes payable 7,028 6,821 Subordinated notes 17,625 15,931 EB-5 promissory notes 42,211 41,404 Working capital loans 3,827 - Term loans on capital expenditures 5,850 5,860 Total debt 294,721 246,240 Less current portion of debt 37,028 49,219 Total long term debt $ 257,693 $ 197,021 Third Eye Capital Note Purchase Agreement On July 6, 2012, On March 8, 2022, No. 22 No. 22” December 31, 2021, ( December 31, 2021. On May 11, 2022, No. 23 No. 23” March 31, 2022, ( March 31, 2023 March 31, 2022 On August 8, 2022, No. 24 No. 24" may April 1, 2024 may No. 24 On March 6, 2023, No. 25 No. 25” March 31, 2023, not 10 On May 4, 2023, No. 26 No. 26” June 30, 2023, not No. 26 470 50 470 60 On May 16, 2023, No. 27 No. 27” may April 1, 2025 may No. 27 470 50 470 60 According to ASC 470 10 45 not 12 four 5 February 2024, one April 1, 2025. December 31, 2023. On March 25, 2024, No. 28 No. 28” 120%. No. 28, No. 28 470 50 On March 6, 2020, one March 14, 2021, August 9, 2021, March 25, 2024, April 1, 2025. April 1, 2025. may may April 1, 2025. Terms of Third Eye Capital Notes A. Term Notes December 31, 2023 April 1, 2025. B. Revolving Credit Facility December 31, 2023 April 1, 2025. December 31, 2023 C. Revolving Notes Series B. December 31, 2023) April 1, 2025. December 31, 2023, D. Revenue Participation Term Notes April 1, 2025. December 31, 2023 E. Acquisition Term Notes December 31, 2023 April 1, 2025. December 31, 2023 not F. Reserve Liquidity Notes . The Reserve Liquidity Notes, with available borrowing capacity in the amount of $85.0 million, accrues interest at the rate of 30% per annum and are due and payable upon the earlier of: (i) the closing of new debt or equity financings, (ii) receipt from any sale, merger, debt or equity financing, or (iii) April 1, 2025. December 31, 2023 . The Third Eye Capital Notes contain various covenants, including but not not twelve The Third Eye Capital Notes are secured by first Third Eye Capital Revolving Credit Facility for Fuels and Carbon Lines. March 2, 2022, two March 1, 2025 ten December 31, 2023 March 1, 2026 eight December 31, 2023 five March 2, 2022; ten March 2, 2022. As of December 31, 2023 GAFI had $33.9 million in principal and interest outstanding and $1.3 million unamortized debt issuance costs. As of December 31, 2023 , ACCI had $25.2 million in principal and interest outstanding and $1.7 million in unamortized debt issuance costs. Cilion shareholder seller notes payable July 6, 2012, December 31, 2023 Subordinated Notes. January 6 January 9, 2012, two six six two may On January 1, 2023, two June 30, 2023; ( two July 1, 2023, two December 31, 2023; ( two January 1, 2023 July 1 2023 470 50 On January 1, 2024, two June 30, 2024; ( two At December 31, 2023 2022 EB- 5 5 March 4, 2011 ( January 19, 2012 July 24, 2012) 5 72 5 2 3%. four 5 one two one no February 27, 2019, 5 six six 5 12 5 19 829 5 three Advanced BioEnergy, LP arranges investments with foreign investors, who each make loans to the Keyes Plant in increments of $0.5 million. The Company has sold an aggregate principal amount of $36.0 million of EB- 5 5 2012 December 31, 2023 December 31, 2023 5 5 On October 16, 2016, 5 5 5 5 November 21, 2019, 5 100 5 May 1, 2020 No. 3 5 60. 5 52 5 may five The Company has sold an aggregate principal amount of $4.0 million of EB- 5 5 2016 December 31, 2023 $4.0 December 31, 2023 5 5 Working capital loans. July 26, 2022, not August 1, 2022, not one December 31, 2023 2022, none, Secured loans . first 2023, November 15, 2023 May 3, 2024. December 31, 2023 December 31, 2022, no Aemetis Biogas 1 October 4, 2022, “AB1 AB1 1 AB1 December 22, 2023, AB1 "AB1 AB1 1 five five January 22, 2024, ( January 22, 2025, December 22, 2042, AB1 2025, AB1 December 31, 2023 December 31, 2022, none, AB1 Aemetis Biogas 2 July 28, 2023, second “AB2 AB2 not 2 five five AB2 August 15, 2023, ( August 15, 2025, July 28, 2043, AB2 2025, AB2 December 31, 2023 December 31, 2022, none, none, AB2 Financing Agreement for capital expenditures. TM We recorded the asset in property, plant and equipment, net and recorded the related liability of $2.0 million in short term borrowings and $3.8 million in other long-term debt, respectively as of December 31, 2023 Debt repayments for the Company’s loan obligations follow: Twelve months ended December 31, Debt Repayments 2024 $ 37,028 2025 181,464 2026 37,912 2027 4,128 2028 2,108 There after 37,545 Total debt 300,185 Debt issuance costs (5,464 ) Total debt, net of debt issuance costs $ 294,721 |
Note 5 - Commitments and Contin
Note 5 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 5. Leases The Company is a party to operating leases for the Company's corporate office in Cupertino, modular offices, and laboratory facilities. We have also entered into several finance leases for mobile equipment and for the Riverbank Industrial Complex. These finance leases have a purchase option at the end of the term that we are reasonably certain we will exercise, so the leases are classified as finance leases. All of our leases have remaining term of one 12 The Company evaluates leases in accordance with ASC 842 The components of lease expense and sublease income is as follows: Twelve Months Ended December 31, 2023 2022 Operating lease cost Operating lease expense $ 722 $ 673 Short term lease expense 223 176 Variable lease expense 93 91 Total operating lease cost $ 1,038 $ 940 Finance lease cost Amortization of right-of-use assets $ 121 $ 179 Interest on lease liabilities 340 310 Total finance lease cost $ 461 $ 489 Cash paid for amounts included in the measurement of lease liabilities: Twelve Months Ended December 31, 2023 2022 Operating cash flows used in operating leases $ 668 $ 766 Operating cash flows used in finance leases 340 310 Financing cash flows used in finance leases 428 481 Supplemental non-cash flow information related to the operating ROU asset and lease liabilities for the year ended December 31, 2023 2022 Twelve Months Ended December 31, 2023 2022 Operating leases Accretion of the lease liability $ 249 $ 340 Amortization of right-of-use assets 293 333 Weighted Average Remaining Lease Term Operating leases (in years) 4.2 5.2 Finance leases (in years) 13.0 14.0 Weighted Average Discount Rate Operating leases 14.1 % 14.2 % Finance leases 13.2 % 13.2 % Supplemental balance sheet information related to leases was as follows: As of December 31, 2023 December 31, 2022 Operating leases Operating lease right-of-use assets $ 2,056 $ 2,449 Current portion of operating lease liability 406 338 Long term operating lease liability 1,783 2,189 Total operating lease liabilities 2,189 2,527 Finance leases Property and equipment, at cost $ 2,889 $ 3,045 Accumulated depreciation (228 ) (112 ) Property and equipment, net 2,661 2,933 Other current liability 30 71 Other long term liabilities 2,687 2,911 Total finance lease liabilities 2,717 2,982 Maturities of operating lease liabilities were as follows: Year Ended December 31, Operating leases Finance leases 2024 $ 682 $ 179 2025 681 168 2026 626 145 2027 645 145 2028 272 145 There after - 10,105 Total lease payments 2,906 10,887 Less imputed interest (717 ) (8,170 ) Total lease liability $ 2,189 $ 2,717 The Company acts as sublessor in certain leasing arrangements, primarily related to land and buildings. Fixed sublease payments received are recognized on a straight-line basis over the sublease term. Sublease income and head lease expense for these transactions are recognized on net basis on the consolidated financial statements. Sublease income is recorded in the other operating income section of the Consolidated Statements of Operations and Comprehensive Loss. The components of lease income for the years ended December 31, 2023 2022 were as follows: December 31, 2023 December 31, 2022 Lease income $ 2,075 $ 1,255 Future lease commitments to be received by the Company as of December 31, 2023 , are as fo Year ended December 31, 2024 $ 948 2025 773 2026 562 2027 508 2028 508 There after 635 Total future lease commitments $ 3,934 Legal Proceedings On August 31, 2016, July 24, 2019, May 6, 2022 second 2022. The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. While the ultimate outcome of these matters is not not |
Note 6 - Aemetis Biogas - Serie
Note 6 - Aemetis Biogas - Series A Preferred Financing and Variable Interest Entity | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Variable Interest Entity Disclosure [Text Block] | 6. Series A Preferred Financing and Variable Interest Entity On December 20, 2018, X ABGL is authorized to issue 11,000,000 common units, and up to 6,000,000 convertible, redeemable, secured, preferred membership units (the “Series A Preferred Units”). ABGL issued 6,000,000 common units to the Company at $5.00 per common unit for a total of $30,000,000 in funding. Additionally, 5,000,000 common units of ABGL are held in reserve as potential conversion units issuable to the Purchaser upon certain triggering events discussed below. Prior to August 8, 2022, second 10 one one one three sixth not Prior to August 8, 2022, may one one December 31, 2023 not may 100% 75% From inception of the agreement to August 8, 2022, first second On August 8th, 2022, December 31, 2022, ( September 30, 2022, January 1, 2023. 470 50 On January 1, 2023, not December 31, 2022, May 31, 2023, June 1, 2023 May 31, 2024, 470 60 no December 31, 2022, seventeen May 31, 2024. On May 31, 2023, not May 31, 2023 August 31, 2023, September 1, 2023 August 31, 2024, 470 60 no May 31, 2023 fifteen August 31, 2024. On October 6, 2023, On November 8, 2023, not August 31, 2023 December 31, 2023, fourth January 1, 2024 December 31, 2024, fourth 470 60 no November 8, 2023 December 31, 2024. On February 8, 2024, not December 31, 2023 April 30, 2024, not May 1, 2024 April 30, 2025, fifth fifth 470. December 31, 2023. The Company recorded carrying value of Series A Preferred Unit liabilities as long-term liabilities of $113.2 million and $116.0 million as of December 31, 2023 2022 , respectively. Variable interest entity assessment After consideration of ABGL’s operations and the above agreement, we concluded that ABGL did not December 31, 2023 |
Note 7 - Stockholders' Equity
Note 7 - Stockholders' Equity | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Equity [Text Block] | 7. Equity Common Stock The Company is authorized to issue 80 million shares of common stock, $0.001 par value per share. Convertible Preferred Stock The company is authorized to issue up to 65 million shares of preferred stock, $0.001 par value per share. Effective as of December 12, 2023, one December 31, 2023, Shares Issued and Authorized Outstanding December 31, Shares 2023 2022 Series B preferred stock 7,235 - 1,270 Undesignated 57,765 - - 65,000 - 1,270 |
Note 8 - Warrants to Purchase C
Note 8 - Warrants to Purchase Common Stocks | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Outstanding Warrants [Text Block] | 8. During 2023, ● A warrant issued to a vendor exercisable for the purchase of 100,000 shares at an exercise price of $2.50 per share with a two 2023 ● Warrants issued to the Company's senior lender exercisable for 160,000 shares of the Company's common stock at an exercise price of $2.00 per share with a five December 31, 2023. ● In connection with a credit line increase, a warrant issued to the Company's senior lender was automatically modified to increase the number of shares that may ● Warrants issued to subordinated lenders exercisable for 226,666 at an exercise price of $0.01 per share and a term of two 2023 The following table shows the weighted average fair value calculations for warrants granted based on the listed weighted average assumptions: Description For the year ended December 31, 2023 2022 Dividend-yield 0 % 0 % Risk-free interest rate 3.85 % 1.75 % Expected volatility 117.90 % 151.41 % Expected life (years) 5 3 Exercise price per share $ 1.62 $ 10.47 Market value per share on grant date $ 4.13 $ 11.29 Fair value per share on grant date $ 3.92 $ 9.68 A summary of historical warrant activity for the years ended December 31, 2023 2022 Warrants Outstanding & Exercisable Weighted - Average Exercise Price Average Remaining Term in Years Outstanding December 31, 2021 55 $ 2.59 4.95 Granted 527 10.47 Exercised (227 ) 0.01 Outstanding December 31, 2022 355 $ 15.92 7.48 Granted 511 1.62 Exercised (336 ) 0.83 Outstanding December 31, 2023 530 $ 11.70 5.77 All of the above outstanding warrants are vested and exercisable as of December 31, 2023 . |
Note 9 - Stock-based Compensati
Note 9 - Stock-based Compensation | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | 9. 2019 On August 26, 2021, 2019 “2019 2019 April 25, 2019, 2019 2019 July 1, 2021, 2019 January 1 January 1 Pursuant to the 2019 December 31, 2023 2022, December 31, 2023 2022, The following table summarizes activity under the 2019 2022 2023: Shares Available for Grant Number of Shares Outstanding Weighted-Average Exercise Price Balance as of December 31, 2021 42 3,763 $ 2.29 Authorized 1,338 - - Options Granted (1,307 ) 1,307 10.97 RSAs Granted (89 ) - - Exercised - (295 ) 0.93 Forfeited/expired 81 (81 ) 11.63 Balance as of December 31, 2022 65 4,694 $ 4.63 Authorized 1,644 - - Options Granted (1,278 ) 1,278 3.60 RSAs Granted (244 ) - - Exercised - (177 ) 1.83 Forfeited/expired 269 (269 ) 5.93 Balance as of December 31, 2023 456 5,526 $ 4.42 The following table summarizes vested and unvested option awards outstanding as of December 31, 2023 2022 Number of Shares Weighted Average Exercise Price Remaining Contractual Term (In Years) Aggregate Intrinsic Value1 2023 Vested and Exercisable 3,986 $ 3.58 6.47 $ 11,695 Unvested 1,540 6.55 8.67 1,621 Total 5,526 $ 4.42 7.04 $ 13,316 2022 Vested and Exercisable 3,170 $ 2.46 6.98 $ 7,419 Unvested 1,524 9.13 8.81 647 Total 4,694 $ 4.63 7.58 $ 8,066 ( 1 Intrinsic value based on the $5.24 and $3.96 closing price of Aemetis, Inc. common stock on December 31, 2023 2022 respectively, as reported on the NASDAQ Exchange. Inducement Equity Plan Options In March 2016, December 31, 2023 not Stock-based Compensation Expense Stock-based compensation is accounted for in accordance with ASC 718, Compensation - Stock Compensation n estimated fair value on the grant date. We estimate the fair value using the Black-Scholes option pricing model and recognize that fair value as an expense over the vesting period of each grant using the straight-line method. W No. 107, Share-Based Payment not zero The weighted average fair value for options granted during the years ended 2023 2022 Description For the year ended December 31, 2023 2022 Dividend-yield 0 % 0 % Risk-free interest rate 3.86 % 2.03 % Expected volatility 124.62 % 117.21 % Expected life (years) 7.00 7.00 Market value per share on grant date $ 3.60 $ 10.97 Fair value per share on grant date $ 3.29 $ 9.71 For the years ended December 31, 2023 2022 $7.7 million, and $6.4 million, respectively. December 31, 2023 |
Note 10 - Agreements
Note 10 - Agreements | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Collaborative Arrangement Disclosure [Text Block] | 10. Working Capital Arrangement. May 2023, As of December 31, 2023 2022 , Aemetis made prepayments to J.D. Heiskell of none December 31, 2023 2022 As of and for the twelve months ended December 31, 2023 2022 Ethanol sales $ 77,359 $ - Wet distiller's grains sales 21,963 50,930 CDO and CDS sales 3,296 10,168 Corn purchases 83,128 191,401 Accounts receivable 1,073 - Accounts payable 1,207 27 Ethanol and Wet Distillers Grains Marketing Arrangement. The Company entered into a Fuel Ethanol Purchase and Sale Agreement with Murex, which matures on October 31, 2023, one May 30, 2023 No. 1 October 1, 2023 March 31, 2025. December 31, 2024, one For the years ended December 31, 2023 2022 sts of $1.5 million and $2.9 million, respectively, For the years ended December 31, 2023 2022 ol $1.7 million and $3.3 million for each period and expensed transportation costs related to sales of WDG of $3.3 million and $5.3 million. Supply Trade Agreement. July 1, 2022, ten one one December 31, 2023 2022 As of December 31, 2023 |
Note 11 - Segment Information
Note 11 - Segment Information | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 11. Aemetis recognizes three The “California Ethanol” reportable segment includes the Company’s 65 million gallon per year ethanol plant in Keyes, California, and the adjacent land leased for the production of CO₂. The “California Dairy Renewable Natural Gas” reportable segment including the production and sale of Renewable Natural Gas and associated environmental attributes, consisting of anaerobic digesters located at diaries, at 36 The “India Biodiesel” reportable segment includes the Company’s 60 million gallon per year nameplate capacity biodiesel manufacturing plant in Kakinada India, and administrative offices in Hyderabad, India. The Company has additional operating segments that were determined not Summarized financial information by reportable segment for the years ended December 31, 2023 2022 For the year ended December 31, 2023 California Ethanol California Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 104,068 $ 5,455 $ 77,194 $ - $ 186,717 Intersegment revenues - - - - - Gross profit (loss) (6,602 ) (331 ) 8,950 - 2,017 Interest expense, including amortization of debt fees 25,258 2,809 447 11,005 39,519 Accretion and other expenses of Series A preferred units - 25,313 - - 25,313 Loss on Income tax expense (benefit) - (55,159 ) 1,416 7 (53,736 ) Capital expenditures 5,695 24,744 1,281 1,399 33,119 Depreciation 3,995 2,116 576 246 6,933 Total Assets 67,991 92,794 34,769 47,852 243,406 For the year ended December 31, 2022 California Ethanol California Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 228,194 $ 208 $ 28,111 $ - $ 256,513 Intersegment revenues - 1,002 - - 1,002 Gross profit (loss) (13,017 ) (778 ) 8,273 (13 ) (5,535 ) Interest expense, including amortization of debt fees 20,637 742 119 7,272 28,770 Accretion and other expenses of Series A preferred units - 9,888 - - 9,888 Income tax expense - 6 1,040 7 1,053 Loss on debt extinguishment - 49,386 - - 49,386 Capital expenditures 8,399 22,884 129 7,745 39,157 Depreciation 4,148 615 650 122 5,535 Total Assets 66,794 77,714 16,120 46,486 207,114 A reconciliation of reportable segment revenues to consolidated totals for the years 2023 2022 Revenues 2023 2022 Total revenues for reportable segments $ 186,717 $ 257,515 Elimination of intersegment revenues - (1,002 ) Total consolidated revenues $ 186,717 $ 256,513 California Ethanol: December 31, 2023 2022 one December 31, 2023 December 31, 2022 December 31, 2022 California Dairy Renewable Natural Gas: twelve December 31, 2023 one third 2023, D3 2023 twelve December 31, 2022, India Biodiesel: December 31, 2023 three December 31, 2022 three |
Note 12 - Related Party Transac
Note 12 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 12. The Company owes Eric McAfee, the Company’s Chairman and CEO, and McAfee Capital LLC (“McAfee Capital”), owned by Eric McAfee and his wife, $0.4 millio n in connection with employment agreements and expense reimbursements. T December 31, 2023. February 28, 2023, one December 31, 2023, The Company owes various members of its Board of Directors amounts totaling $0.3 million as of December 31, 2023 December 31, 2022 December 31, 2023 2022 |
Note 13 - Income Tax
Note 13 - Income Tax | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 13. The Company files a consolidated federal income tax return including all its domestic subsidiaries except for Aemetis Biogas LLC, which files its own returns. State tax returns are filed on a consolidated, combined or separate basis depending on the applicable laws relating to the Company and its subsidiaries. Components of tax expense consist of the following: 2023 2022 Current: Federal $ (55,164 ) $ - State and Local 13 13 Foreign 1,489 230 (53,662 ) 243 Deferred: Federal - - State and Local - - Foreign (74 ) 810 Income tax (benefit) expense $ (53,736 ) $ 1,053 The Company records deferred tax liability in other long term liabilities in the Consolidated Balance Sheets. The deferred tax liability resulted as India subsidiary had income for the year ended December 31, 2023 Year Ended December 31, 2023 2022 United States $ (107,191 ) $ (112,959 ) Foreign 7,035 6,254 Pretax loss $ (100,156 ) $ (106,705 ) Income tax benefit differs from the amounts computed by applying the statutory U.S. federal income tax rate ( 21% Year Ended December 31, 2023 2022 Income tax benefit at the federal statutory rate $ (21,033 ) $ (22,408 ) State tax benefit (999 ) (496 ) Sale of tax credits (55,164 ) - Foreign tax differential 11 168 Stock-based compensation 2,048 295 Interest Expense 92 58 GILTI Inclusion - 1,126 Prior year true-ups (18,031 ) 55 Non-includible US Entities - 13,499 Other 67 46 Credits (869 ) (2,373 ) Valuation Allowance 40,142 11,083 Income Tax Expense (Benefit) (53,736 ) 1,053 Effective Tax Rate 53.65 % (0.99 )% The components of the net deferred tax asset or (liability) are as follows: Year Ended December 31, 2023 2022 Deferred Tax Assets Organizational Costs, Start-up and Intangible Assets $ 34,217 $ 2,309 Stock Based Compensation 1,239 1,842 NOLs, Unabsorbed Depreciation and R&D Credits C/F's 67,621 68,201 Interest expense carryover 29,066 22,374 Ethanol Credits 1,500 1,500 Carbon Oxide Sequestration Credit 6,696 5,827 Accrued Expenses 2,249 2,001 Operating Lease Liability 1,282 1,512 Other, net 248 113 Total Deferred Tax Assets 144,118 105,679 Valuation Allowance (135,354 ) (95,214 ) Net Deferred Tax Assets 8,764 10,465 Deferred Tax Liabilities Right of Use Asset (1,230 ) (1,477 ) Property, Plant & Equipment (8,266 ) (9,788 ) Other, net (3 ) (10 ) Total Deferred Tax Liabilities (9,499 ) (11,275 ) Net Deferred Tax Liabilities $ (735 ) $ (810 ) Based on the Company’s evaluation of current and anticipated future taxable income, the Company believes it is more likely than not We do not December 31, 2023 2022 December 31, 2022. may not ASC 740 not not not 12 December 31, 2023 not The following describes the open tax years, by major tax jurisdiction, as of December 31, 2023 United States — Federal 2007 – present United States — State 2008 – present India 2013 – present Mauritius 2006 – present As of December 31, 2023 2027 2043. 2027 2042. may December 31, 2023 no |
Note 14 - Parent Company Financ
Note 14 - Parent Company Financial Statements (Unaudited) | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Condensed Financial Information of Parent Company Only Disclosure [Text Block] | 14. We conduct substantially all of our operations through subsidiaries and are dependent on cash distributions, dividends and other intercompany transfers of funds from our operations. Our subsidiaries have not may not Aemetis, Inc. (Parent Company) Balance Sheets As of December 31, 2023 2022 2023 2022 Assets Current assets Cash and cash equivalents $ 1,454 $ 286 Receivables due from subsidiaries 110,083 98,780 Prepaid expenses 437 611 Other current assets 12 7 Total current assets 111,986 99,684 Investment in Aemetis Property Keyes, Inc. 1,556 1,274 Investment in Aemetis International, Inc. 12,059 6,659 Investment in Aemetis Advanced Products Riverbank, Inc. 638 173 Investment in AE Advanced Products Keyes , Inc. 246 - Total investments in Subsidiaries, net of advances 14,499 8,106 Property, plant and equipment, net 149 135 Other assets 2,096 2,377 Total Assets $ 128,730 $ 110,302 Liabilities & stockholders' deficit Current liabilities Accounts payable $ 3,633 $ 2,934 Mandatorily redeemable Series B convertible preferred 4,521 4,082 Other current liabilities 5,031 4,269 Total current liabilities 13,185 11,285 Long term liabilities: Operating lease liability 1,716 2,047 Subsidiary obligation in excess of investment Investment in AE Advanced Fuels, Inc. 220,571 177,856 Investment in Aemetis Americas, Inc 202 205 Investment in Aemetis Biofuels, Inc. 2,721 2,738 Investment in Aemetis Technologies, Inc. 4,868 4,716 Investment in AE Advanced Products Keyes , Inc. - 270 Investment in Aemetis Health Products, Inc. 2,084 2,076 Investment in Goodland Advanced Fuels, Inc. 22,982 16,869 Investment in Aemetis Biogas LLC 70,471 91,292 Investment in Aemetis Carbon Capture Inc 5,895 2,323 Investment in Aemetis Properties Riverbank, Inc. 1,012 479 Total subsidiary obligation in excess of investment 330,806 298,824 Total long term liabilities 332,522 300,871 Stockholders' deficit Series B Preferred convertible stock - 1 Common stock 41 36 Additional paid-in capital 264,058 232,546 Accumulated deficit (475,405 ) (428,985 ) Accumulated other comprehensive loss (5,671 ) (5,452 ) Total stockholders' deficit (216,977 ) (201,854 ) Total liabilities & stockholders' deficit $ 128,730 $ 110,302 Aemetis, Inc. (Parent Company) Statements of Operations and Comprehensive Loss For the Years Ended December 31, 2023 2022 2023 2022 Equity in subsidiary losses $ (25,370 ) $ (91,561 ) Selling, general and administrative expenses 19,218 15,203 Operating loss (44,588 ) (106,764 ) Other (income) expense Interest expense 1,073 806 Debt related fees and amortization expense 781 1,581 Other income (30 ) (1,400 ) Loss before income taxes (46,412 ) (107,751 ) Income tax expense 8 7 Net loss (46,420 ) (107,758 ) Other comprehensive loss Foreign currency translation adjustment (219 ) (1,102 ) Comprehensive loss $ (46,639 ) $ (108,860 ) Aemetis, Inc. (Parent Company) Statements of Cash Flows For the years ended December 31, 2023 2022 2023 2022 Operating activities: Net loss (46,420 ) (107,758 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 7,660 6,410 Depreciation 51 29 Debt related fees and amortization expense 782 1,776 Subsidiary portion of net losses 25,370 91,561 Gain on litigation - (1,400 ) Warrants issued for working capital agreement 409 - Changes in assets and liabilities: Prepaid expenses (608 ) 111 Accounts payable 699 (90 ) Accrued interest expense 785 778 Other liabilities 85 (4,625 ) Other assets 276 207 Net cash used in operating activities (10,911 ) (13,001 ) Investing activities: Capital expenditures (65 ) (128 ) Subsidiary advances, net (9,707 ) 1,222 Net cash provided by (used in) investing activities (9,772 ) 1,094 Financing activities: Proceeds from the exercise of stock options 133 206 Proceeds from issuance of common stock in equity offering 21,718 11,987 Net cash provided by financing activities 21,851 12,193 Net increase in cash, cash equivalents, and restricted cash 1,168 286 Cash, cash equivalents and restricted cash at beginning of period 286 - Cash, cash equivalents, and restricted cash at end of period $ 1,454 $ 286 Supplemental disclosures of cash flow information, cash paid: Income taxes paid 7 7 Supplemental disclosures of cash flow information, non-cash transactions: Fair value of warrants issued to subordinated debt holders 1,278 1,939 Fair value of stock issued to a related party for guarantee fees - 2,012 Fair value of warrants issued for capital expenditures 318 - Fair value of warrants issued to lender for debt issuance costs - 3,158 Fair value of stock issued to lender - 1,335 |
Note 15 - Subsequent Events
Note 15 - Subsequent Events | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 15. Subordinated Notes On January 1, 2024, two June 30, 2024; ( not two Series A Preferred Unit Purchase Agreement On February 8, 2024, April 30, 2024, twelve not Third Eye Capital Reserve Liquidity Facility On March 25, 2024, $85 April 1, 2025. April 1, 2025. 30% 40% may 2% may April 1, 2025. Third Eye Capital Limited Waiver and Amendment No. 28 On March 25, 2024, No. 28 No. 28” 120%. No. 28, |
Note 16 - Liquidity
Note 16 - Liquidity | 12 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | 16. Liquidity The accompanying financial statements have been prepared contemplating the realization of assets and satisfaction of liabilities in the normal course of business. As a result of negative capital, negative operating results, and collateralization of substantially all of the Company assets, the Company has been reliant on its senior secured lender to provide additional funding and has been required to remit substantially all excess cash from operations to the senior secured lender. In order to meet our obligations during the next twelve April 1, 2025, twelve December 31, 2023. Operations and Project Development For the Keyes Plant, we plan to operate the plant and continue to improve its financial performance by adopting new technologies or process changes that allow for energy efficiency, cost reduction, or revenue enhancements, as well as, execute upon awarded grants that improve energy and operational efficiencies resulting in lower cost, lower carbon emissions, and overall margin improvement. For Aemetis Biogas, we plan to operate our existing biogas digesters to produce and sell Renewable Natural Gas (RNG) and the associated Federal D3 2023 2024, For the Kakinada Plant, we plan to continue to sell our biodiesel to OMCs pursuant to cost-plus contracts. We are also continuing to upgrade the plant to increase feedstock flexibility (and thereby lower feedstock costs), increase production capacity, and produce new products. Additionally, we are in the process of obtaining approval and contractual arrangements for the export of refined animal tallow into international markets. Financing We plan to continue to locate funding for existing and new business opportunities through a combination of working with our senior lender, restructuring existing loan agreements, entering into additional debt agreements for specific projects, obtaining project specific equity and debt for development projects, and obtaining additional debt from the current EB- 5 |
Insider Trading Arrangements
Insider Trading Arrangements | 12 Months Ended |
Dec. 31, 2023 shares | |
ecd_TradingArrByIndTable | |
Material Terms of Trading Arrangement [Text Block] | 9B. Other Information. (a) Current Reports On March 25, 2024, two No. 28 4, 15, 8 two 10.36 10.37, two 8 10.36 10.37. (b) Adoption and Termination 10b5 1 On September 15, 2023 Francis P. Barton Board of Directors adopted 10b5 1 December 15, 2023, ( December 31, 2024, ( may 10b5 1 On September 15, 2023 Todd A. Waltz Executive Vice President and Chief Financial Officer adopted 10b5 1 January 1, 2024, ( June 15, 2025, ( may 10b5 1 December 31, 2023, 475,000 No On November 13, 2023 Andrew B. Foster Executive Vice President and Chief Operating Officer adopted 10b5 1 February 14, 2024, ( December 31, 2024, ( may 10b5 1 10b5 1 December 31, 2023, 96,000 No |
Non-Rule 10b5-1 Arrangement Adopted [Flag] | false |
Non-Rule 10b5-1 Arrangement Terminated [Flag] | false |
Rule 10b5-1 Arrangement Terminated [Flag] | false |
AMTX_Francis P. Barton [Member] | |
ecd_TradingArrByIndTable | |
Trading Arrangement, Securities Aggregate Available Amount | 126,000 |
Trading Arrangement Adoption Date | September 15, 2023 |
Trading Arrangement, Individual Name | Francis P. Barton |
Trading Arrangement, Individual Title | Board of Directors Member |
Rule 10b5-1 Arrangement Adopted [Flag] | true |
AMTX, Todd A. Waltz [Member] | |
ecd_TradingArrByIndTable | |
Trading Arrangement, Securities Aggregate Available Amount | 475,000 |
Trading Arrangement Adoption Date | September 15, 2023 |
Trading Arrangement, Individual Name | Todd A. Waltz |
Trading Arrangement, Individual Title | Executive Vice President and Chief Financial Officer |
Rule 10b5-1 Arrangement Adopted [Flag] | true |
AMTX_Andrew B. Foster [Member] | |
ecd_TradingArrByIndTable | |
Trading Arrangement, Securities Aggregate Available Amount | 199,616 |
Trading Arrangement Adoption Date | November 13, 2023 |
Trading Arrangement, Individual Name | Andrew B. Foster |
Trading Arrangement, Individual Title | Executive Vice President and Chief Operating Officer |
Rule 10b5-1 Arrangement Adopted [Flag] | true |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation and Consolidation. not All intercompany balances and transactions have been eliminated in consolidation. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates |
Revenue [Policy Text Block] | Revenue Recognition 606 California Ethanol: 2022 second 2023, second 2023, not Given the similarity of the individual sales transactions with J.D. Heiskell, we have assessed them as a portfolio of similar contracts. Prior to May 25, 2023, May 25, 2023, one During the last two December 2022, first second 2023 May 2023. The following table shows our sales in California Ethanol by product category: California Ethanol For the twelve months ended December 31, 2023 2022 Ethanol sales $ 78,403 $ 165,876 Wet distiller's grains sales 21,963 50,930 Other sales 3,702 11,388 $ 104,068 $ 228,194 California Dairy Renewable Natural Gas: December 31, 2023, seven 26 2023, seven "D3 D3 third 2023 first 2024. D3 Dairy Renewable Natural Gas For the twelve months ended December 31, 2023 2022 Molecule and RIN sales $ 5,455 $ 208 India Biodiesel: not one The following table shows our sales in India by product category: India Biodiesel For the twelve months ended December 31, 2023 2022 Biodiesel sales $ 74,503 $ 27,041 Other sales 2,691 1,070 $ 77,194 $ 28,111 |
Cost of Goods and Service [Policy Text Block] | Cost of Goods Sold January May 2023, |
Shipping and Handling Costs [Policy Text Block] | Shipping and Handling Costs |
Research and Development Expense, Policy [Policy Text Block] | Research and Development. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash, Cash Equivalents, and Restricted Cash three may not AB1 AB2 The following table reconciles cash, cash equivalents, and restricted cash reported in the Consolidated Balance Sheet to the total of the same such amounts shown in the statement of cash flows. As of December 31, 2023 December 31, 2022 Cash and cash equivalents $ 2,667 $ 4,313 Restricted cash included in other current assets 289 725 Restricted cash included in other assets 3,324 1,961 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 6,280 $ 6,999 |
Receivable [Policy Text Block] | Accounts Receivable. The Company sells all of its products to J.D. Heiskell under the J.D. Heiskell Purchasing Agreement. Our third may 30 The Company maintains an allowance for doubtful accounts for balances that appear to have specific collection issues and estimates an allowance for expected credit losses. The collection process is based on the age of the invoice and requires attempted contacts with the customer at specified intervals. If, after a specified number of days, the Company has been unsuccessful in its collection efforts, a bad debt allowance is recorded for the balance in question. Delinquent accounts receivables are charged against the allowance for doubtful accounts once un-collectability has been determined. The factors considered in reaching this determination are the apparent financial condition of the customer and the Company’s success in contacting and negotiating with the customer. If the financial condition of the Company’s customers were to deteriorate, additional allowances may |
Inventory, Policy [Policy Text Block] | Inventories first first |
Other Current Assets Policy [Policy Text Block] | Other current assets |
Consolidation, Variable Interest Entity, Policy [Policy Text Block] | Variable Interest Entities. 1 2 not |
Property, Plant and Equipment, Policy [Policy Text Block] | Property, Plant and Equipment. The Company evaluates the recoverability of long-lived assets with finite lives in accordance with ASC Subtopic 360 10 35 Property Plant and Equipment Subsequent Measurement, may not may not not December 31, 2023 2022 |
Government Assistance [Policy Text Block] | Grants Received. California Energy Commission Low-Carbon Fuel Production Program December 31, 2023 California Department of Food and Agriculture Dairy Digester Research and Development Grant 2 019, two second 2021. October 2020, six 2020 December 31, 2023 California Energy Commission Low Carbon Advanced Ethanol Grant Program. May 2019, not not not December 31, 2023 2022 U.S. Department of Food and Agriculture Forest Service Grant. December 31, 2023 California Energy Commission Grant for Solar Microgrid, DSC and Battery Backup System. 1.56 1.25MW/2.5MWh December 31, 2023 California Department of Forestry and Fire Protection Grant. May 2022. 2 100% December 31, 2023 California Department of Forestry and Fire Protection Grant. May 2022. December 31, 2023 U.S. Forest Service Community Wood Grant. May 2022. 3 no December 31, 2023 USDA Biofuel Producer Program Grant. second 2022, 19 California Energy Commission Grant for Mechanical Vapor Recompression System. December 31, 2023 PG&E A2313 February 2023, Pacific Gas and Electric SEM Manufacturer s Incentive Program. fourth 2022, |
Regulatory Income Taxes, Policy [Policy Text Block] | Investment Tax Credits. third 2023, third 740 December 31, 2023. October 2023, |
Income Tax, Policy [Policy Text Block] | Income Taxes 740 Income Taxes 740 not may not December 31, 2023 2022 The Company is subject to income tax audits by the respective tax authorities in all of the jurisdictions in which it operates. The determination of tax liabilities in each of these jurisdictions requires the interpretation and application of complex and sometimes uncertain tax laws and regulations. The recognition and measurement of current taxes payable or refundable and deferred tax assets and liabilities requires that the Company make certain estimates and judgments. Changes to these estimates or a change in judgment may In 2018, 1 2 |
Earnings Per Share, Policy [Policy Text Block] | Basic and Diluted Net Income (Loss) per Share. December 31, 2023 2022 The following table shows the number of potentially dilutive shares excluded from the diluted net loss per share calculation as of December 31, 2023 2022 As of December 31, 2023 December 31, 2022 Series B preferred (post split basis) - 127 Common stock options and warrants 6,056 5,050 Debt with conversion feature at $ 30 1,267 1,240 Total number of potentially dilutive shares excluded from the diluted net (loss) per share calculation 7,323 6,417 |
Comprehensive Income, Policy [Policy Text Block] | Comprehensive Loss. 220 Comprehensive Income not |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign Currency Translation/Transactions. |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments. not 3 |
Share-Based Payment Arrangement [Policy Text Block] | Share Based Compensation. ize share-based compensation expense in accordance with ASC 718 Stock Compensation, which requires the Company to recognize expenses related to the estimated fair value of the Company’s share-based compensation awards over the vesting period, adjusted to reflect only those shares that are expected to vest. |
Commitments and Contingencies, Policy [Policy Text Block] | Commitments and Contingencies. 450 Contingencies 450 one |
Debt, Policy [Policy Text Block] | Convertible Instruments. Debt Issuance Costs. Troubled Debt Restructuring Accounting. Debt Modification Accounting 540 50 Debt Modification and Extinguishments 10 10 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Pronouncements In November 2023, 2023 07, 280 2023 07, 280 January 1, 2024, January 1, 2025. 2023 07 In December 2023, 2023 09, 740 January 1, 2025, 2023 09 There were no |
Note 1 - Nature of Activities_2
Note 1 - Nature of Activities and Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Disaggregation of Revenue [Table Text Block] | California Ethanol For the twelve months ended December 31, 2023 2022 Ethanol sales $ 78,403 $ 165,876 Wet distiller's grains sales 21,963 50,930 Other sales 3,702 11,388 $ 104,068 $ 228,194 Dairy Renewable Natural Gas For the twelve months ended December 31, 2023 2022 Molecule and RIN sales $ 5,455 $ 208 India Biodiesel For the twelve months ended December 31, 2023 2022 Biodiesel sales $ 74,503 $ 27,041 Other sales 2,691 1,070 $ 77,194 $ 28,111 |
Schedule of Cash and Cash Equivalents [Table Text Block] | As of December 31, 2023 December 31, 2022 Cash and cash equivalents $ 2,667 $ 4,313 Restricted cash included in other current assets 289 725 Restricted cash included in other assets 3,324 1,961 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 6,280 $ 6,999 |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | As of December 31, 2023 December 31, 2022 Series B preferred (post split basis) - 127 Common stock options and warrants 6,056 5,050 Debt with conversion feature at $ 30 1,267 1,240 Total number of potentially dilutive shares excluded from the diluted net (loss) per share calculation 7,323 6,417 |
Note 2 - Inventories (Tables)
Note 2 - Inventories (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | As of December 31, 2023 December 31, 2022 Raw materials $ 9,907 $ 2,971 Work-in-progress 1,682 127 Finished goods 6,702 1,560 Total inventories $ 18,291 $ 4,658 |
Note 3 - Property, Plant and _2
Note 3 - Property, Plant and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | As of December 31, 2023 December 31, 2022 Land $ 7,345 $ 7,344 Plant and buildings 136,318 99,116 Furniture and fixtures 2,266 1,831 Machinery and equipment 14,982 15,209 Construction in progress 73,057 88,990 Property held for development 15,431 15,437 Finance lease right of use assets 2,889 3,045 Total gross property, plant & equipment 252,288 230,972 Less accumulated depreciation (57,180 ) (50,531 ) Total net property, plant & equipment $ 195,108 $ 180,441 |
Depreciation Of Property, Plant, and Equipment [Table Text Block] | Years Plant and buildings 20 - 30 Machinery and equipment 5 - 15 Furniture and fixtures 3 - 5 |
Note 4 - Debt (Tables)
Note 4 - Debt (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | December 31, 2023 December 31, 2022 Third Eye Capital term notes $ 7,159 $ 7,141 Third Eye Capital revolving credit facility 20,922 60,602 Third Eye Capital revolving notes Series B 54,412 - Third Eye Capital revenue participation term notes 12,011 11,963 Third Eye Capital acquisition term notes 26,655 26,578 Third Eye Capital Fuels Revolving Line 32,511 27,410 Third Eye Capital Carbon Revolving Line 23,486 22,710 Construction Loan 41,024 19,820 Cilion shareholder seller notes payable 7,028 6,821 Subordinated notes 17,625 15,931 EB-5 promissory notes 42,211 41,404 Working capital loans 3,827 - Term loans on capital expenditures 5,850 5,860 Total debt 294,721 246,240 Less current portion of debt 37,028 49,219 Total long term debt $ 257,693 $ 197,021 |
Schedule of Maturities of Long-Term Debt [Table Text Block] | Twelve months ended December 31, Debt Repayments 2024 $ 37,028 2025 181,464 2026 37,912 2027 4,128 2028 2,108 There after 37,545 Total debt 300,185 Debt issuance costs (5,464 ) Total debt, net of debt issuance costs $ 294,721 |
Note 5 - Commitments and Cont_2
Note 5 - Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Lease, Cost [Table Text Block] | Twelve Months Ended December 31, 2023 2022 Operating lease cost Operating lease expense $ 722 $ 673 Short term lease expense 223 176 Variable lease expense 93 91 Total operating lease cost $ 1,038 $ 940 Finance lease cost Amortization of right-of-use assets $ 121 $ 179 Interest on lease liabilities 340 310 Total finance lease cost $ 461 $ 489 Twelve Months Ended December 31, 2023 2022 Operating cash flows used in operating leases $ 668 $ 766 Operating cash flows used in finance leases 340 310 Financing cash flows used in finance leases 428 481 |
Supplemental Non-cash Flow Information Related to Leases [Table Text Block] | Twelve Months Ended December 31, 2023 2022 Operating leases Accretion of the lease liability $ 249 $ 340 Amortization of right-of-use assets 293 333 Weighted Average Remaining Lease Term Operating leases (in years) 4.2 5.2 Finance leases (in years) 13.0 14.0 Weighted Average Discount Rate Operating leases 14.1 % 14.2 % Finance leases 13.2 % 13.2 % |
Supplemental Balance Sheet Information Related to Leases [Table Text Block] | As of December 31, 2023 December 31, 2022 Operating leases Operating lease right-of-use assets $ 2,056 $ 2,449 Current portion of operating lease liability 406 338 Long term operating lease liability 1,783 2,189 Total operating lease liabilities 2,189 2,527 Finance leases Property and equipment, at cost $ 2,889 $ 3,045 Accumulated depreciation (228 ) (112 ) Property and equipment, net 2,661 2,933 Other current liability 30 71 Other long term liabilities 2,687 2,911 Total finance lease liabilities 2,717 2,982 |
Lease Term [Table Text Block] | Year Ended December 31, Operating leases Finance leases 2024 $ 682 $ 179 2025 681 168 2026 626 145 2027 645 145 2028 272 145 There after - 10,105 Total lease payments 2,906 10,887 Less imputed interest (717 ) (8,170 ) Total lease liability $ 2,189 $ 2,717 |
Operating Lease, Lease Income [Table Text Block] | December 31, 2023 December 31, 2022 Lease income $ 2,075 $ 1,255 |
Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block] | Year ended December 31, 2024 $ 948 2025 773 2026 562 2027 508 2028 508 There after 635 Total future lease commitments $ 3,934 |
Note 7 - Stockholders' Equity (
Note 7 - Stockholders' Equity (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Stock by Class [Table Text Block] | Shares Issued and Authorized Outstanding December 31, Shares 2023 2022 Series B preferred stock 7,235 - 1,270 Undesignated 57,765 - - 65,000 - 1,270 |
Note 8 - Warrants to Purchase_2
Note 8 - Warrants to Purchase Common Stocks (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Warrants, Valuation Assumptions [Table Text Block] | Description For the year ended December 31, 2023 2022 Dividend-yield 0 % 0 % Risk-free interest rate 3.85 % 1.75 % Expected volatility 117.90 % 151.41 % Expected life (years) 5 3 Exercise price per share $ 1.62 $ 10.47 Market value per share on grant date $ 4.13 $ 11.29 Fair value per share on grant date $ 3.92 $ 9.68 |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Warrants Outstanding & Exercisable Weighted - Average Exercise Price Average Remaining Term in Years Outstanding December 31, 2021 55 $ 2.59 4.95 Granted 527 10.47 Exercised (227 ) 0.01 Outstanding December 31, 2022 355 $ 15.92 7.48 Granted 511 1.62 Exercised (336 ) 0.83 Outstanding December 31, 2023 530 $ 11.70 5.77 |
Note 9 - Stock-based Compensa_2
Note 9 - Stock-based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] | Shares Available for Grant Number of Shares Outstanding Weighted-Average Exercise Price Balance as of December 31, 2021 42 3,763 $ 2.29 Authorized 1,338 - - Options Granted (1,307 ) 1,307 10.97 RSAs Granted (89 ) - - Exercised - (295 ) 0.93 Forfeited/expired 81 (81 ) 11.63 Balance as of December 31, 2022 65 4,694 $ 4.63 Authorized 1,644 - - Options Granted (1,278 ) 1,278 3.60 RSAs Granted (244 ) - - Exercised - (177 ) 1.83 Forfeited/expired 269 (269 ) 5.93 Balance as of December 31, 2023 456 5,526 $ 4.42 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block] | Number of Shares Weighted Average Exercise Price Remaining Contractual Term (In Years) Aggregate Intrinsic Value1 2023 Vested and Exercisable 3,986 $ 3.58 6.47 $ 11,695 Unvested 1,540 6.55 8.67 1,621 Total 5,526 $ 4.42 7.04 $ 13,316 2022 Vested and Exercisable 3,170 $ 2.46 6.98 $ 7,419 Unvested 1,524 9.13 8.81 647 Total 4,694 $ 4.63 7.58 $ 8,066 |
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Description For the year ended December 31, 2023 2022 Dividend-yield 0 % 0 % Risk-free interest rate 3.86 % 2.03 % Expected volatility 124.62 % 117.21 % Expected life (years) 7.00 7.00 Market value per share on grant date $ 3.60 $ 10.97 Fair value per share on grant date $ 3.29 $ 9.71 |
Note 10 - Agreements (Tables)
Note 10 - Agreements (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] | As of and for the twelve months ended December 31, 2023 2022 Ethanol sales $ 77,359 $ - Wet distiller's grains sales 21,963 50,930 CDO and CDS sales 3,296 10,168 Corn purchases 83,128 191,401 Accounts receivable 1,073 - Accounts payable 1,207 27 |
Note 11 - Segment Information (
Note 11 - Segment Information (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | For the year ended December 31, 2023 California Ethanol California Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 104,068 $ 5,455 $ 77,194 $ - $ 186,717 Intersegment revenues - - - - - Gross profit (loss) (6,602 ) (331 ) 8,950 - 2,017 Interest expense, including amortization of debt fees 25,258 2,809 447 11,005 39,519 Accretion and other expenses of Series A preferred units - 25,313 - - 25,313 Loss on Income tax expense (benefit) - (55,159 ) 1,416 7 (53,736 ) Capital expenditures 5,695 24,744 1,281 1,399 33,119 Depreciation 3,995 2,116 576 246 6,933 Total Assets 67,991 92,794 34,769 47,852 243,406 For the year ended December 31, 2022 California Ethanol California Dairy Renewable Natural Gas India Biodiesel All other Total Revenues from external customers $ 228,194 $ 208 $ 28,111 $ - $ 256,513 Intersegment revenues - 1,002 - - 1,002 Gross profit (loss) (13,017 ) (778 ) 8,273 (13 ) (5,535 ) Interest expense, including amortization of debt fees 20,637 742 119 7,272 28,770 Accretion and other expenses of Series A preferred units - 9,888 - - 9,888 Income tax expense - 6 1,040 7 1,053 Loss on debt extinguishment - 49,386 - - 49,386 Capital expenditures 8,399 22,884 129 7,745 39,157 Depreciation 4,148 615 650 122 5,535 Total Assets 66,794 77,714 16,120 46,486 207,114 |
Reconciliation of Revenue from Segments to Consolidated [Table Text Block] | Revenues 2023 2022 Total revenues for reportable segments $ 186,717 $ 257,515 Elimination of intersegment revenues - (1,002 ) Total consolidated revenues $ 186,717 $ 256,513 |
Note 13 - Income Tax (Tables)
Note 13 - Income Tax (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | 2023 2022 Current: Federal $ (55,164 ) $ - State and Local 13 13 Foreign 1,489 230 (53,662 ) 243 Deferred: Federal - - State and Local - - Foreign (74 ) 810 Income tax (benefit) expense $ (53,736 ) $ 1,053 |
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | Year Ended December 31, 2023 2022 United States $ (107,191 ) $ (112,959 ) Foreign 7,035 6,254 Pretax loss $ (100,156 ) $ (106,705 ) |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Year Ended December 31, 2023 2022 Income tax benefit at the federal statutory rate $ (21,033 ) $ (22,408 ) State tax benefit (999 ) (496 ) Sale of tax credits (55,164 ) - Foreign tax differential 11 168 Stock-based compensation 2,048 295 Interest Expense 92 58 GILTI Inclusion - 1,126 Prior year true-ups (18,031 ) 55 Non-includible US Entities - 13,499 Other 67 46 Credits (869 ) (2,373 ) Valuation Allowance 40,142 11,083 Income Tax Expense (Benefit) (53,736 ) 1,053 Effective Tax Rate 53.65 % (0.99 )% |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | Year Ended December 31, 2023 2022 Deferred Tax Assets Organizational Costs, Start-up and Intangible Assets $ 34,217 $ 2,309 Stock Based Compensation 1,239 1,842 NOLs, Unabsorbed Depreciation and R&D Credits C/F's 67,621 68,201 Interest expense carryover 29,066 22,374 Ethanol Credits 1,500 1,500 Carbon Oxide Sequestration Credit 6,696 5,827 Accrued Expenses 2,249 2,001 Operating Lease Liability 1,282 1,512 Other, net 248 113 Total Deferred Tax Assets 144,118 105,679 Valuation Allowance (135,354 ) (95,214 ) Net Deferred Tax Assets 8,764 10,465 Deferred Tax Liabilities Right of Use Asset (1,230 ) (1,477 ) Property, Plant & Equipment (8,266 ) (9,788 ) Other, net (3 ) (10 ) Total Deferred Tax Liabilities (9,499 ) (11,275 ) Net Deferred Tax Liabilities $ (735 ) $ (810 ) |
Summary of Income Tax Examinations [Table Text Block] | United States — Federal 2007 – present United States — State 2008 – present India 2013 – present Mauritius 2006 – present |
Note 14 - Parent Company Fina_2
Note 14 - Parent Company Financial Statements (Unaudited) (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Condensed Balance Sheet [Table Text Block] | 2023 2022 Assets Current assets Cash and cash equivalents $ 1,454 $ 286 Receivables due from subsidiaries 110,083 98,780 Prepaid expenses 437 611 Other current assets 12 7 Total current assets 111,986 99,684 Investment in Aemetis Property Keyes, Inc. 1,556 1,274 Investment in Aemetis International, Inc. 12,059 6,659 Investment in Aemetis Advanced Products Riverbank, Inc. 638 173 Investment in AE Advanced Products Keyes , Inc. 246 - Total investments in Subsidiaries, net of advances 14,499 8,106 Property, plant and equipment, net 149 135 Other assets 2,096 2,377 Total Assets $ 128,730 $ 110,302 Liabilities & stockholders' deficit Current liabilities Accounts payable $ 3,633 $ 2,934 Mandatorily redeemable Series B convertible preferred 4,521 4,082 Other current liabilities 5,031 4,269 Total current liabilities 13,185 11,285 Long term liabilities: Operating lease liability 1,716 2,047 Subsidiary obligation in excess of investment Investment in AE Advanced Fuels, Inc. 220,571 177,856 Investment in Aemetis Americas, Inc 202 205 Investment in Aemetis Biofuels, Inc. 2,721 2,738 Investment in Aemetis Technologies, Inc. 4,868 4,716 Investment in AE Advanced Products Keyes , Inc. - 270 Investment in Aemetis Health Products, Inc. 2,084 2,076 Investment in Goodland Advanced Fuels, Inc. 22,982 16,869 Investment in Aemetis Biogas LLC 70,471 91,292 Investment in Aemetis Carbon Capture Inc 5,895 2,323 Investment in Aemetis Properties Riverbank, Inc. 1,012 479 Total subsidiary obligation in excess of investment 330,806 298,824 Total long term liabilities 332,522 300,871 Stockholders' deficit Series B Preferred convertible stock - 1 Common stock 41 36 Additional paid-in capital 264,058 232,546 Accumulated deficit (475,405 ) (428,985 ) Accumulated other comprehensive loss (5,671 ) (5,452 ) Total stockholders' deficit (216,977 ) (201,854 ) Total liabilities & stockholders' deficit $ 128,730 $ 110,302 |
Condensed Income Statement [Table Text Block] | 2023 2022 Equity in subsidiary losses $ (25,370 ) $ (91,561 ) Selling, general and administrative expenses 19,218 15,203 Operating loss (44,588 ) (106,764 ) Other (income) expense Interest expense 1,073 806 Debt related fees and amortization expense 781 1,581 Other income (30 ) (1,400 ) Loss before income taxes (46,412 ) (107,751 ) Income tax expense 8 7 Net loss (46,420 ) (107,758 ) Other comprehensive loss Foreign currency translation adjustment (219 ) (1,102 ) Comprehensive loss $ (46,639 ) $ (108,860 ) |
Condensed Cash Flow Statement [Table Text Block] | 2023 2022 Operating activities: Net loss (46,420 ) (107,758 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 7,660 6,410 Depreciation 51 29 Debt related fees and amortization expense 782 1,776 Subsidiary portion of net losses 25,370 91,561 Gain on litigation - (1,400 ) Warrants issued for working capital agreement 409 - Changes in assets and liabilities: Prepaid expenses (608 ) 111 Accounts payable 699 (90 ) Accrued interest expense 785 778 Other liabilities 85 (4,625 ) Other assets 276 207 Net cash used in operating activities (10,911 ) (13,001 ) Investing activities: Capital expenditures (65 ) (128 ) Subsidiary advances, net (9,707 ) 1,222 Net cash provided by (used in) investing activities (9,772 ) 1,094 Financing activities: Proceeds from the exercise of stock options 133 206 Proceeds from issuance of common stock in equity offering 21,718 11,987 Net cash provided by financing activities 21,851 12,193 Net increase in cash, cash equivalents, and restricted cash 1,168 286 Cash, cash equivalents and restricted cash at beginning of period 286 - Cash, cash equivalents, and restricted cash at end of period $ 1,454 $ 286 Supplemental disclosures of cash flow information, cash paid: Income taxes paid 7 7 Supplemental disclosures of cash flow information, non-cash transactions: Fair value of warrants issued to subordinated debt holders 1,278 1,939 Fair value of stock issued to a related party for guarantee fees - 2,012 Fair value of warrants issued for capital expenditures 318 - Fair value of warrants issued to lender for debt issuance costs - 3,158 Fair value of stock issued to lender - 1,335 |
Note 1 - Nature of Activities_3
Note 1 - Nature of Activities and Summary of Significant Accounting Policies (Details Textual) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||
Feb. 28, 2023 USD ($) | May 31, 2022 USD ($) | Oct. 31, 2020 USD ($) | Dec. 31, 2022 USD ($) | Jun. 30, 2022 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2019 USD ($) | |
Number of Operating Segments | 3 | |||||||
U.S. Department of Food And Agriculture Forest Service [Member] | ||||||||
Awarded Grants | $ 245 | |||||||
Proceeds from Grantors | 166,000 | |||||||
LCFPP [Member] | ||||||||
Awarded Grants | 4,200 | |||||||
Proceeds from Grantors | 3,800 | |||||||
CDFAs[Member] | ||||||||
Awarded Grants | $ 7,800 | $ 3,200 | ||||||
Proceeds from Grantors | 6,200 | |||||||
CEC [Member] | ||||||||
Matching Contribution | 7,900 | |||||||
Actual Expenses Incurred | 5,000 | |||||||
Unearned Grant Proceeds | 1,700 | $ 1,700 | ||||||
CEC [Member] | Maximum [Member] | ||||||||
Awarded Grants | $ 5,000 | |||||||
California Energy Commission Grant for Solar Microgrid, DSC and Battery Backup System [Member] | ||||||||
Awarded Grants | 8,000 | |||||||
Proceeds from Grantors | 4,400 | |||||||
Matching Contribution | 1,600 | |||||||
CAL FIRE Business and Workforce Development Grant Program [Member] | ||||||||
Awarded Grants | $ 2,000 | |||||||
Proceeds from Grantors | 0 | |||||||
Matching Contribution | 5,800 | |||||||
CAL Fire [Member] | ||||||||
Awarded Grants | 500 | |||||||
Proceeds from Grantors | 0 | |||||||
US Forest Service [Member] | ||||||||
Awarded Grants | 642 | |||||||
USDA Bioguel Producer Program [Member] | ||||||||
Proceeds from Grantors | $ 14,200 | |||||||
Matching Contribution | $ 2,400 | |||||||
California Energy Commission Grant for Mechanical Vapor Recompression System [Member] | ||||||||
Awarded Grants | 6,000 | |||||||
Proceeds from Grantors | 0 | |||||||
Matching Contribution | 5,300 | |||||||
CEC PG&E Pipeline Interconnect [Member] | ||||||||
Proceeds from Grantors | $ 5,000 | |||||||
PG&E SEM Incentive Program [Member] | ||||||||
Proceeds from Grantors | $ 374 | |||||||
Other Receivable [Member] | ||||||||
Accumulated Deferred Investment Tax Credit | 55,200 | |||||||
India Biodiesel [Member] | Other Current Assets [Member] | ||||||||
Tax Credit Carryforward, Amount | 1,600 | |||||||
Nontrade Receivables, Current | 69 | |||||||
Accounts and Other Receivables, Net, Current | $ 1,200 |
Note 1 - Nature of Activities_4
Note 1 - Nature of Activities and Summary of Significant Accounting Policies - Schedule of America By Product Category (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Sales | $ 77,194 | $ 28,111 |
California Ethanol [Member] | ||
Sales | 104,068 | 228,194 |
California Ethanol [Member] | Alternative Energy, Ethanol [Member] | ||
Sales | 78,403 | 165,876 |
California Ethanol [Member] | Wet Distillers Grains [Member] | ||
Sales | 21,963 | 50,930 |
California Ethanol [Member] | Product and Service, Other [Member] | ||
Sales | 3,702 | 11,388 |
California Dairy Renewable Natural Gas [Member] | Gas Molecules and RIN Credits [Member] | ||
Sales | 5,455 | 208 |
India Biodiesel [Member] | Renewable Energy, Biodiesel [Member] | ||
Sales | 74,503 | 27,041 |
India Biodiesel [Member] | Product and Service, Other [Member] | ||
Sales | $ 2,691 | $ 1,070 |
Note 1 - Nature of Activities_5
Note 1 - Nature of Activities and Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Cash and cash equivalents | $ 2,667 | $ 4,313 |
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows | 6,280 | 6,999 |
Other Current Assets [Member] | ||
Restricted cash | 289 | 725 |
Other Assets [Member] | ||
Restricted cash | $ 3,324 | $ 1,961 |
Note 1 - Nature of Activities_6
Note 1 - Nature of Activities and Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details) - shares shares in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Total Number of Potentially Dilutive Shares Excluded from the basic and diluted net loss per share calculation (in shares) | 7,323 | 6,417 |
Series B Convertible Preferred Stock [Member] | ||
Total Number of Potentially Dilutive Shares Excluded from the basic and diluted net loss per share calculation (in shares) | 0 | 127 |
Common Stock Options and Warrants [Member] | ||
Total Number of Potentially Dilutive Shares Excluded from the basic and diluted net loss per share calculation (in shares) | 6,056 | 5,050 |
Debt with Conversion Feature [Member] | ||
Total Number of Potentially Dilutive Shares Excluded from the basic and diluted net loss per share calculation (in shares) | 1,267 | 1,240 |
Note 1 - Nature of Activities_7
Note 1 - Nature of Activities and Summary of Significant Accounting Policies - Schedule of Dilutive Securities (Details) (Parentheticals) - $ / shares | Dec. 31, 2023 | Dec. 31, 2022 |
Debt with Conversion Feature [Member] | ||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 30 | $ 30 |
Note 2 - Inventories (Details T
Note 2 - Inventories (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Inventory Write-down | $ 58 | $ 100 |
Note 2 - Inventories - Schedule
Note 2 - Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Raw materials | $ 9,907 | $ 2,971 |
Work-in-progress | 1,682 | 127 |
Finished goods | 6,702 | 1,560 |
Total inventories | $ 18,291 | $ 4,658 |
Note 3 - Property, Plant and _3
Note 3 - Property, Plant and Equipment (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Capitalized Interest Costs, Including Allowance for Funds Used During Construction | $ 5,600 | $ 11,100 |
Depreciation | $ 6,933 | $ 5,535 |
Note 3 - Property, Plant and _4
Note 3 - Property, Plant and Equipment - Schedule of Property, Plant, and Equipment (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Land | $ 7,345 | $ 7,344 |
Plant and buildings | 136,318 | 99,116 |
Furniture and fixtures | 2,266 | 1,831 |
Machinery and equipment | 14,982 | 15,209 |
Construction in progress | 73,057 | 88,990 |
Property held for development | 15,431 | 15,437 |
Total gross property, plant & equipment | 252,288 | 230,972 |
Less accumulated depreciation | (57,180) | (50,531) |
Total net property, plant & equipment | 195,108 | 180,441 |
Property, Plant and Equipment [Member] | ||
Finance lease right of use assets | $ 2,889 | $ 3,045 |
Note 3 - Property, Plant and _5
Note 3 - Property, Plant and Equipment - Depreciation of Property, Plant, and Equipment (Details) | Dec. 31, 2023 |
Minimum [Member] | Building [Member] | |
Useful life (Year) | 20 years |
Minimum [Member] | Machinery and Equipment [Member] | |
Useful life (Year) | 5 years |
Minimum [Member] | Furniture and Fixtures [Member] | |
Useful life (Year) | 3 years |
Maximum [Member] | Building [Member] | |
Useful life (Year) | 30 years |
Maximum [Member] | Machinery and Equipment [Member] | |
Useful life (Year) | 15 years |
Maximum [Member] | Furniture and Fixtures [Member] | |
Useful life (Year) | 5 years |
Note 4 - Debt (Details Textual)
Note 4 - Debt (Details Textual) $ / shares in Units, gal in Millions | Jan. 01, 2024 USD ($) $ / shares shares | Jul. 28, 2023 USD ($) | Jul. 01, 2023 USD ($) $ / shares shares | May 16, 2023 USD ($) $ / shares shares | Jan. 01, 2023 USD ($) $ / shares shares | Oct. 04, 2022 USD ($) | Mar. 02, 2022 USD ($) $ / shares shares | Mar. 06, 2020 USD ($) | Jul. 06, 2012 USD ($) | Mar. 04, 2011 USD ($) | Mar. 25, 2024 USD ($) | Mar. 22, 2024 USD ($) | Dec. 31, 2023 USD ($) $ / shares | Sep. 30, 2023 USD ($) | May 04, 2023 USD ($) gal | Mar. 31, 2023 | Mar. 06, 2023 USD ($) | Dec. 31, 2022 USD ($) $ / shares | Aug. 08, 2022 USD ($) | Aug. 01, 2022 USD ($) | Jul. 26, 2022 USD ($) | May 11, 2022 USD ($) | Mar. 08, 2022 USD ($) | Dec. 31, 2021 $ / shares | Aug. 09, 2021 USD ($) | Mar. 14, 2021 USD ($) | May 01, 2020 USD ($) | Nov. 21, 2019 USD ($) | Feb. 27, 2019 $ / shares | Oct. 16, 2016 USD ($) | Jan. 09, 2012 USD ($) $ / shares | Jan. 06, 2012 USD ($) |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 11.7 | $ 15.92 | $ 2.59 | |||||||||||||||||||||||||||||
Long-Term Debt, Total | $ 294,721,000 | |||||||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years 9 months 7 days | 7 years 5 months 23 days | 4 years 11 months 12 days | |||||||||||||||||||||||||||||
Short-Term Debt | $ 23,443,000 | $ 36,754,000 | ||||||||||||||||||||||||||||||
Debt, Long-Term and Short-Term, Combined Amount | 294,721,000 | 246,240,000 | ||||||||||||||||||||||||||||||
Other Long-Term Debt, Noncurrent | 51,717,000 | 11,678,000 | ||||||||||||||||||||||||||||||
Stock Issued Under Fuels Revolving Line [Member] | ||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | shares | 100,000 | |||||||||||||||||||||||||||||||
Five Year Warrants in Connection With New Credit Facility [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 50,000 | |||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 10.2 | |||||||||||||||||||||||||||||||
Ten Year Warrants in Connection With New Credit Facility [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 250,000 | |||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 20 | |||||||||||||||||||||||||||||||
Warrants in Connection With Subordinated Notes [Member] | AAFK [Member] | ||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 2 years | 2 years | 2 years | |||||||||||||||||||||||||||||
Class of Warrant or Right, Issued (in shares) | shares | 113,000 | 113,000 | ||||||||||||||||||||||||||||||
Warrants in Connection With Subordinated Notes [Member] | Subsequent Event [Member] | AAFK [Member] | ||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 113,000 | |||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.01 | |||||||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 2 years | |||||||||||||||||||||||||||||||
Class of Warrant or Right, Issued (in shares) | shares | 113 | |||||||||||||||||||||||||||||||
Revolving Credit Facility [Member] | ||||||||||||||||||||||||||||||||
Repayments of Long-Term Lines of Credit | $ 16,000,000 | |||||||||||||||||||||||||||||||
Property Taxes Payment | 6,100,000 | |||||||||||||||||||||||||||||||
Capital Revolving Credit Facility Fuels And Carbon Lines [Member] | GAFI and ACCI [Member] | ||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | 100,000,000 | |||||||||||||||||||||||||||||||
Fuels Revolving Line [Member] | GAFI [Member] | ||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | 50,000,000 | |||||||||||||||||||||||||||||||
Carbon Revolving Line [Member] | ACCI [Member] | ||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 50,000,000 | |||||||||||||||||||||||||||||||
Third Eye Capital [Member] | Mr. McAfee [Member] | ||||||||||||||||||||||||||||||||
Net Amount at Risk by Product and Guarantee, Net Amount at Risk | 8,000,000 | |||||||||||||||||||||||||||||||
Third Eye Capital [Member] | Warrants in Association With Amendment No. 27 [Member] | ||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 80,000 | |||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 2 | |||||||||||||||||||||||||||||||
Third Eye Capital [Member] | Revolving Credit Facility [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 18,000,000 | |||||||||||||||||||||||||||||||
Long-Term Debt, Total | 21,900,000 | |||||||||||||||||||||||||||||||
Debt Issuance Costs, Net | $ 900,000 | |||||||||||||||||||||||||||||||
Third Eye Capital [Member] | Revolving Credit Facility [Member] | Prime Rate [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 22.25% | |||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 13.75% | |||||||||||||||||||||||||||||||
Third Eye Capital [Member] | Acquisition Term Notes [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 15,000,000 | |||||||||||||||||||||||||||||||
Third Eye Capital [Member] | Revolving Notes Series B [Member] | ||||||||||||||||||||||||||||||||
Long-Term Debt, Total | $ 54,800,000 | |||||||||||||||||||||||||||||||
Debt Issuance Costs, Net | $ 400,000 | |||||||||||||||||||||||||||||||
Third Eye Capital [Member] | Revolving Notes Series B [Member] | Prime Rate [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 22.25% | |||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 13.75% | |||||||||||||||||||||||||||||||
Third Eye Capital [Member] | Reserve Liquidity Facility [Member] | ||||||||||||||||||||||||||||||||
Line of Credit Facility, Current Borrowing Capacity | $ 85,000,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 30% | |||||||||||||||||||||||||||||||
Long-Term Debt, Total | $ 0 | |||||||||||||||||||||||||||||||
Term Loan [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 7,200,000 | |||||||||||||||||||||||||||||||
Revenue Participation Term Notes [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,000,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5% | |||||||||||||||||||||||||||||||
Revenue Participation Term Notes [Member] | Third Eye Capital [Member] | AAFK [Member] | ||||||||||||||||||||||||||||||||
Long-Term Debt, Total | $ 12,100,000 | |||||||||||||||||||||||||||||||
Debt Issuance Costs, Net | $ 81,000 | |||||||||||||||||||||||||||||||
Amendment No. 22 [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | $ 100,000 | |||||||||||||||||||||||||||||||
Amendment No. 23 [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | $ 100,000 | |||||||||||||||||||||||||||||||
Amendment No. 24 [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | $ 300,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Extension Fee, Percent of Note Indebtedness | 1% | |||||||||||||||||||||||||||||||
Amendment No. 25 [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | $ 100,000 | |||||||||||||||||||||||||||||||
Amendment No. 26 [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | $ 100,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Minimum Production Requirement (Gallon) | gal | 10 | |||||||||||||||||||||||||||||||
Amendment No. 27 [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | $ 500,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Extension Fee, Percent of Note Indebtedness | 1% | |||||||||||||||||||||||||||||||
Amendment No 28 [Member] | Third Eye Capital [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | $ 100,000 | |||||||||||||||||||||||||||||||
Reserve Liquidity Facility [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 18,000,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Term (Year) | 1 year | |||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 70,000,000 | |||||||||||||||||||||||||||||||
Line of Credit Facility, Current Borrowing Capacity | $ 40,000,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Non-refundable Standby Fee, Percent of Difference Between Principal Amount and the Commitment | 2% | |||||||||||||||||||||||||||||||
Non Refundable Fees | $ 500,000 | |||||||||||||||||||||||||||||||
Reserve Liquidity Facility [Member] | Third Eye Capital [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | 500,000 | |||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 85,000,000 | $ 85,000,000 | ||||||||||||||||||||||||||||||
Reserve Liquidity Facility Paid Monthly in Arrears [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 30% | |||||||||||||||||||||||||||||||
Reserve Liquidity Facility if Event of Default Occurred and Continues [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 40% | |||||||||||||||||||||||||||||||
Term Notes [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 14% | |||||||||||||||||||||||||||||||
Long-Term Debt, Total | $ 7,200,000 | |||||||||||||||||||||||||||||||
Debt Issuance Costs, Net | 45,000 | |||||||||||||||||||||||||||||||
Acquisition Term Notes [Member] | Third Eye Capital [Member] | ||||||||||||||||||||||||||||||||
Long-Term Debt, Total | 26,800,000 | |||||||||||||||||||||||||||||||
Debt Issuance Costs, Net | 184,000 | |||||||||||||||||||||||||||||||
Acquisition Term Notes [Member] | Third Eye Capital [Member] | Aemetis Facility Keyes, Inc. [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Redemption Fee | $ 7,500,000 | |||||||||||||||||||||||||||||||
Acquisition Term Notes [Member] | Third Eye Capital [Member] | Prime Rate [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 19.25% | |||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 10.75% | |||||||||||||||||||||||||||||||
Fuels Revolving Line [Member] | GAFI [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10% | 14.50% | ||||||||||||||||||||||||||||||
Long-Term Debt, Total | $ 33,900,000 | |||||||||||||||||||||||||||||||
Debt Issuance Costs, Net | $ 1,300,000 | |||||||||||||||||||||||||||||||
Fuels Revolving Line [Member] | Prime Rate [Member] | GAFI [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 6% | |||||||||||||||||||||||||||||||
Carbon Revolving Line [Member] | ACCI [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8% | 12.50% | ||||||||||||||||||||||||||||||
Long-Term Debt, Total | $ 25,200,000 | |||||||||||||||||||||||||||||||
Debt Issuance Costs, Net | 1,700,000 | |||||||||||||||||||||||||||||||
Carbon Revolving Line [Member] | Prime Rate [Member] | ACCI [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 4% | |||||||||||||||||||||||||||||||
Cilion Shareholder Seller Notes Payable [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 5,000,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 3% | |||||||||||||||||||||||||||||||
Long-Term Debt, Total | 7,000,000 | |||||||||||||||||||||||||||||||
Debt, Long-Term and Short-Term, Combined Amount | 7,028,000 | 6,821,000 | ||||||||||||||||||||||||||||||
Subordinated Notes [Member] | AAFK [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | $ 2,500,000 | $ 900,000 | ||||||||||||||||||||||||||||||
Debt Instrument Fee Rate | 10% | |||||||||||||||||||||||||||||||
Debt Extension Fee, Percentage | 10% | |||||||||||||||||||||||||||||||
Short-Term Debt | 17,600,000 | 15,900,000 | ||||||||||||||||||||||||||||||
Subordinated Notes 1 [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt | 17,625,000 | 15,931,000 | ||||||||||||||||||||||||||||||
Subordinated Notes 1 [Member] | AAFK [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Cash Extension Fee | $ 90,000 | $ 90,000 | ||||||||||||||||||||||||||||||
Subordinated Notes 1 [Member] | Subsequent Event [Member] | AAFK [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Cash Extension Fee | $ 90,000 | |||||||||||||||||||||||||||||||
Subordinated Notes 2 [Member] | AAFK [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Cash Extension Fee | $ 250,000 | $ 250,000 | ||||||||||||||||||||||||||||||
Subordinated Notes 2 [Member] | Subsequent Event [Member] | AAFK [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Cash Extension Fee | $ 250,000 | |||||||||||||||||||||||||||||||
EB5 Phase I Notes [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 500,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Term (Year) | 4 years | |||||||||||||||||||||||||||||||
Long-Term Debt, Total | 37,900,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 30 | |||||||||||||||||||||||||||||||
Debt Instrument, Amount Released From Escrow | 35,500,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Amount Remaining Funded to Escrow | 500,000 | |||||||||||||||||||||||||||||||
EB5 Phase I Notes [Member] | Scenario, Plan [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 50,000,000 | |||||||||||||||||||||||||||||||
EB5 Phase I Notes [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Investment Raised Per Investor | $ 500,000 | |||||||||||||||||||||||||||||||
EB5 Phase I Funding [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 36,000,000 | |||||||||||||||||||||||||||||||
EB5 Phase I Funding [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 36,000,000 | |||||||||||||||||||||||||||||||
EB5 Phase II Notes [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 3% | |||||||||||||||||||||||||||||||
Debt Instrument, Amount Remaining Funded to Escrow | 46,800,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Principal Amount Sold | 4,000,000 | |||||||||||||||||||||||||||||||
Debt, Long-Term and Short-Term, Combined Amount | 4,300,000 | |||||||||||||||||||||||||||||||
EB5 Phase II Notes [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Minimum Investment Raised Per Investor | $ 900,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Investment Raised Per Investor | 900,000 | |||||||||||||||||||||||||||||||
Aggregate Principal Amount | $ 50,800,000 | |||||||||||||||||||||||||||||||
EB5 Phase II Notes [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Minimum Investment Raised Per Investor | $ 500,000 | |||||||||||||||||||||||||||||||
Secunderabad Oils [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | |||||||||||||||||||||||||||||||
Short-Term Debt | 3,800,000 | 0 | ||||||||||||||||||||||||||||||
Debt Agreement, Maximum Borrowing Capacity | $ 1,880,000 | |||||||||||||||||||||||||||||||
Leo Edibles & Fats Limited [Member] | ||||||||||||||||||||||||||||||||
Debt Agreement, Maximum Borrowing Capacity | $ 1,270,000 | |||||||||||||||||||||||||||||||
IndusInd Bank and HDFC Bank Secured Loans [Member] | ||||||||||||||||||||||||||||||||
Short-Term Debt | 0 | 0 | ||||||||||||||||||||||||||||||
IndusInd Bank and HDFC Bank Secured Loans [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8% | |||||||||||||||||||||||||||||||
IndusInd Bank and HDFC Bank Secured Loans [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6% | |||||||||||||||||||||||||||||||
Construction Loan Agreement [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.25% | |||||||||||||||||||||||||||||||
Long-Term Debt, Total | 25,100,000 | 0 | ||||||||||||||||||||||||||||||
Debt, Long-Term and Short-Term, Combined Amount | 41,024,000 | 19,820,000 | ||||||||||||||||||||||||||||||
Debt Agreement, Maximum Borrowing Capacity | $ 25,000,000 | |||||||||||||||||||||||||||||||
Construction Loan Agreement [Member] | US Treasury (UST) Interest Rate [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 5% | |||||||||||||||||||||||||||||||
Construction Loan Agreement 2 [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.75% | |||||||||||||||||||||||||||||||
Long-Term Debt, Total | 16,800,000 | 0 | ||||||||||||||||||||||||||||||
Debt Issuance Costs, Net | 800,000 | $ 0 | ||||||||||||||||||||||||||||||
Debt Agreement, Maximum Borrowing Capacity | $ 25,000,000 | |||||||||||||||||||||||||||||||
Construction Loan Agreement 2 [Member] | US Treasury (UST) Interest Rate [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 5% | |||||||||||||||||||||||||||||||
Financing Agreement For Capital Expenditures [Member] | ||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 5,700,000 | |||||||||||||||||||||||||||||||
Short-Term Debt | 2,000,000 | |||||||||||||||||||||||||||||||
Other Long-Term Debt, Noncurrent | $ 3,800,000 |
Note 4 - Debt- Schedule of Debt
Note 4 - Debt- Schedule of Debt (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Debt, Long-Term and Short-Term, Combined Amount | $ 294,721 | $ 246,240 |
Short-Term Debt | 23,443 | 36,754 |
Less current portion of debt | 37,028 | 49,219 |
Total long term debt | 257,693 | 197,021 |
Third Eye Capital Term Notes [Member] | ||
Debt, Long-Term and Short-Term, Combined Amount | 7,159 | 7,141 |
Third Eye Capital Revolving Credit Facility [Member] | ||
Debt, Long-Term and Short-Term, Combined Amount | 20,922 | 60,602 |
Revolving Notes Series B [Member] | ||
Debt, Long-Term and Short-Term, Combined Amount | 54,412 | 0 |
Third Eye Capital Revenue Participation Term Notes [Member] | ||
Debt, Long-Term and Short-Term, Combined Amount | 12,011 | 11,963 |
Third Eye Capital Acquisition Term Notes [Member] | ||
Debt, Long-Term and Short-Term, Combined Amount | 26,655 | 26,578 |
Third Eye Capital Fuels Revolving Line [Member] | ||
Debt, Long-Term and Short-Term, Combined Amount | 32,511 | 27,410 |
Third Eye Capital Carbon Revolving Line [Member] | ||
Debt, Long-Term and Short-Term, Combined Amount | 23,486 | 22,710 |
Construction Loan Agreement [Member] | ||
Debt, Long-Term and Short-Term, Combined Amount | 41,024 | 19,820 |
Cilion Shareholder Seller Notes Payable [Member] | ||
Debt, Long-Term and Short-Term, Combined Amount | 7,028 | 6,821 |
Subordinated Notes 1 [Member] | ||
Short-Term Debt | 17,625 | 15,931 |
EB-5 Promissory Notes [Member] | ||
Debt, Long-Term and Short-Term, Combined Amount | 42,211 | 41,404 |
Working capital Loan [Member] | ||
Short-Term Debt | 3,827 | 0 |
Term Loan On Equipment Purchase [Member] | ||
Debt, Long-Term and Short-Term, Combined Amount | $ 5,850 | $ 5,860 |
Note 4 - Debt - Maturities of L
Note 4 - Debt - Maturities of Long-term Debt (Details) $ in Thousands | Dec. 31, 2023 USD ($) |
2024 | $ 37,028 |
2025 | 181,464 |
2026 | 37,912 |
2027 | 4,128 |
2028 | 2,108 |
There after | 37,545 |
Total debt | 300,185 |
Debt issuance costs | (5,464) |
Total debt, net of debt issuance costs | $ 294,721 |
Note 5 - Commitments and Cont_3
Note 5 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||
May 06, 2022 | Jun. 30, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Jun. 24, 2019 | |
Estimated Litigation Liability, Current | $ 6,200 | ||||
Litigation Settlement, Amount Awarded to Other Party | $ 4,800 | ||||
Gain (Loss) Related to Litigation Settlement | $ 1,400 | $ 0 | $ 1,400 | ||
Payments for Legal Settlements | $ 4,800 | ||||
Minimum [Member] | |||||
Lease Term (Year) | 1 year | ||||
Maximum [Member] | |||||
Lease Term (Year) | 13 years |
Note 5 - Commitments and Cont_4
Note 5 - Commitments and Contingencies - Lease Cost (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating lease expense | $ 722 | $ 673 |
Short term lease expense | 223 | 176 |
Variable lease expense | 93 | 91 |
Total operating lease cost | 1,038 | 940 |
Amortization of right-of-use assets | 121 | 179 |
Interest on lease liabilities | 340 | 310 |
Total finance lease cost | 461 | 489 |
Operating cash flows used in operating leases | 668 | 766 |
Operating cash flows used in finance leases | 340 | 310 |
Financing cash flows used in finance leases | $ 428 | $ 481 |
Note 5 - Commitments and Cont_5
Note 5 - Commitments and Contingencies - Non-cash Flow Information Related to ROU Asset and Lease Liabilities (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Accretion of the lease liability | $ 249 | $ 340 |
Amortization of right-of-use assets | $ 293 | $ 333 |
Operating leases (in years) (Year) | 4 years 2 months 12 days | 5 years 2 months 12 days |
Finance leases (in years) (Year) | 13 years | 14 years |
Operating leases | 14.10% | 14.20% |
Finance leases | 13.20% | 13.20% |
Note 5 - Commitments and Cont_6
Note 5 - Commitments and Contingencies - Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Operating lease right-of-use assets | $ 2,056 | $ 2,449 |
Current portion of operating lease liability | 406 | 338 |
Operating lease liability | 1,783 | 2,189 |
Total operating lease liabilities | 2,189 | 2,527 |
Total finance lease liabilities | 2,717 | |
Property, Plant and Equipment [Member] | ||
Property and equipment, at cost | 2,889 | 3,045 |
Accumulated depreciation | (228) | (112) |
Property and equipment, net | 2,661 | 2,933 |
Other Current Liabilities [Member] | ||
Other current liability | 30 | 71 |
Other Noncurrent Liabilities [Member] | ||
Other long term liabilities | 2,687 | 2,911 |
Other Liabilities [Member] | ||
Total finance lease liabilities | $ 2,717 | $ 2,982 |
Note 5 - Commitments and Cont_7
Note 5 - Commitments and Contingencies - Maturities of Leases (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
2024, Operating leases | $ 682 | |
2024, Finance leases | 179 | |
2025, Operating leases | 681 | |
2025, Finance leases | 168 | |
2026, Operating leases | 626 | |
2026, Finance leases | 145 | |
2027, Operating leases | 645 | |
2027, Finance leases | 145 | |
2028, Operating leases | 272 | |
2028, Finance leases | 145 | |
Thereafter, Operating leases | 0 | |
Thereafter, Finance leases | 10,105 | |
Total lease payments, Operating leases | 2,906 | |
Total lease payments, Finance leases | 10,887 | |
Less imputed interest, Operating leases | (717) | |
Less imputed interest, Finance leases | (8,170) | |
Total operating lease liability | 2,189 | $ 2,527 |
Total finance lease liability | $ 2,717 |
Note 5 - Commitments and Cont_8
Note 5 - Commitments and Contingencies - Lease Income (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Lease income | $ 2,075 | $ 1,255 |
Note 5 - Commitments and Cont_9
Note 5 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands | Dec. 31, 2023 USD ($) |
2024 | $ 948 |
2025 | 773 |
2026 | 562 |
2027 | 508 |
2028 | 508 |
There after | 635 |
Total future lease commitments | $ 3,934 |
Note 6 - Aemetis Biogas - Ser_2
Note 6 - Aemetis Biogas - Series A Preferred Financing and Variable Interest Entity (Details Textual) - USD ($) | 12 Months Ended | 14 Months Ended | 15 Months Ended | 17 Months Ended | 44 Months Ended | ||||||||||
Nov. 08, 2023 | Oct. 06, 2023 | Aug. 31, 2023 | May 31, 2023 | Feb. 08, 2023 | Jan. 01, 2023 | Aug. 08, 2022 | Dec. 20, 2018 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 24, 2024 | Aug. 31, 2024 | May 31, 2024 | Aug. 08, 2022 | Feb. 08, 2024 | |
Payments for Repurchase of Redeemable Convertible Preferred Stock | $ 30,000,000 | $ 0 | |||||||||||||
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent | 113,200,000 | 116,000,000 | |||||||||||||
Assets | 243,406,000 | 207,114,000 | |||||||||||||
California Dairy Renewable Natural Gas [Member] | |||||||||||||||
Assets | 92,794,000 | 77,714,000 | |||||||||||||
California Dairy Renewable Natural Gas [Member] | Asset Pledged as Collateral [Member] | Aemetis Biogas LLC [Member] | Preferred Units Series A [Member] | |||||||||||||||
Assets | $ 90,300,000 | ||||||||||||||
Carbon Revolving Line [Member] | |||||||||||||||
Extinguishment of Debt, Gain (Loss), Net of Tax | $ (49,400,000) | ||||||||||||||
Common Units [Member] | |||||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 5,000,000 | ||||||||||||||
Preferred Units Series A [Member] | |||||||||||||||
Common Units Authorized (in shares) | 11,000,000 | ||||||||||||||
Preferred Units, Authorized (in shares) | 6,000,000 | ||||||||||||||
Preferred Unit Dividend Rate Per Dollar Amount (in dollars per share) | $ 0.5 | ||||||||||||||
Conversion of Stock, Shares Issued (in shares) | 1,200,000 | 5,000,000 | |||||||||||||
Maximum Number of Shares (in shares) | 5,000,000 | ||||||||||||||
Redeemable Noncontrolling Interest, Equity, Preferred, Redemption Value per Unit (in dollars per share) | $ 15 | ||||||||||||||
Free Cash Flow Generated by ABGL | 75% | 100% | |||||||||||||
Redeemable Noncontrolling Interest Equity Redemption Value, Total | $ 90,000,000 | ||||||||||||||
Fees and Commission Transfer Agent | 900,000 | ||||||||||||||
Debt Instrument, Collateral Amount | $ 30,000,000 | ||||||||||||||
Preferred Units Series A [Member] | First Tranche [Member] | |||||||||||||||
Preferred Units, Issued (in shares) | 3,200,000 | 3,200,000 | |||||||||||||
Preferred Units Issued Value | $ 16,000,000 | ||||||||||||||
Preferred Units Series A [Member] | Second Tranche [Member | |||||||||||||||
Preferred Units, Issued (in shares) | 2,800,000 | 2,800,000 | |||||||||||||
Preferred Units Issued Value | $ 14,000,000 | ||||||||||||||
Stock Redeemed or Called During Period, Shares (in shares) | 20,000 | ||||||||||||||
Preferred Units Redeemed, Value | $ 300,000 | ||||||||||||||
Preferred Units Series A [Member] | Third Eye Capital [Member] | |||||||||||||||
Sale of Stock, Number of Shares Issued in Transaction (in shares) | 6,000,000 | ||||||||||||||
Series A Preferred Stocks [Member] | |||||||||||||||
Common Units Issued (in shares) | 6,000,000 | ||||||||||||||
Common Units Issuance Value (in dollars per share) | $ 5 | ||||||||||||||
Proceeds from Issuance of Common Units | $ 30,000,000 | ||||||||||||||
PUPA Second Amendment [Member] | |||||||||||||||
Preferred Units Issued Value | $ 116,000,000 | $ 116,000,000 | |||||||||||||
PUPA Second Amendment [Member] | Forecast [Member] | |||||||||||||||
Preferred Units Issued Value | $ 159,000,000 | ||||||||||||||
PUPA Second Amendment [Member] | ABGL [Member] | |||||||||||||||
Preferred Units Issued Value | $ 125,000,000 | $ 106,000,000 | |||||||||||||
PUPA Third Amendment [Member] | |||||||||||||||
Preferred Units Issued Value | $ 127,200,000 | ||||||||||||||
Payments for Repurchase of Redeemable Convertible Preferred Stock | $ 30,000,000 | ||||||||||||||
Proceeds from Sale of Income Tax Credits | $ 55,200,000 | ||||||||||||||
PUPA Third Amendment [Member] | Forecast [Member] | |||||||||||||||
Preferred Units Issued Value | $ 171,700,000 | ||||||||||||||
PUPA Third Amendment [Member] | ABGL [Member] | |||||||||||||||
Preferred Units Issued Value | $ 135,000,000 | ||||||||||||||
PUPA Fourth Amendment [Member] | |||||||||||||||
Preferred Units Issued Value | $ 110,600,000 | ||||||||||||||
Preferred Stock, Redemption Amount | 108,000,000 | ||||||||||||||
Closing Fee | $ 5,500,000 | ||||||||||||||
PUPA Fourth Amendment [Member] | Subsequent Event [Member] | |||||||||||||||
Closing Fee | $ 5,500,000 | ||||||||||||||
PUPA Fourth Amendment [Member] | Forecast [Member] | |||||||||||||||
Increase in Carrying Amount of Redeemable Preferred Stock | $ 130,000,000 | ||||||||||||||
PUPA Fifth Amendment [Member] | |||||||||||||||
Preferred Units Issued Value | $ 111,000,000 | ||||||||||||||
PUPA Fifth Amendment [Member] | Subsequent Event [Member] | |||||||||||||||
Preferred Stock, Redemption Amount | $ 111,000,000 |
Note 7 - Stockholders' Equity_2
Note 7 - Stockholders' Equity (Details Textual) - $ / shares | Dec. 31, 2023 | Dec. 31, 2022 |
Common Stock, Shares Authorized (in shares) | 80,000,000 | 80,000,000 |
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | $ 0.001 |
Series B Preferred Stock [Member] | ||
Preferred Units, Authorized (in shares) | 65,000,000 | |
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | |
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 10 | |
Preferred Stock, Shares Outstanding (in shares) | 0 |
Note 7 - Stockholders' Equity -
Note 7 - Stockholders' Equity - Schedule of Stock by Class (Details) - shares shares in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Series B Preferred Stock, Authorized (in shares) | 65,000 | |
Series B Preferred Stock, Shares Issued (in shares) | 0 | 1,270 |
Series B Preferred Stock [Member] | ||
Series B Preferred Stock, Authorized (in shares) | 7,235 | |
Series B Preferred Stock, Shares Issued (in shares) | 0 | 1,270 |
Undesignated [Member] | ||
Series B Preferred Stock, Authorized (in shares) | 57,765 | |
Series B Preferred Stock, Shares Issued (in shares) | 0 | 0 |
Note 8 - Warrants to Purchase_3
Note 8 - Warrants to Purchase Common Stocks (Details Textual) - $ / shares | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 11.7 | $ 15.92 | $ 2.59 |
Warrants and Rights Outstanding, Term (Year) | 5 years 9 months 7 days | 7 years 5 months 23 days | 4 years 11 months 12 days |
Warrants to Purchase Common Stock [Member] | Vendor [Member] | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 100,000 | ||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.5 | ||
Warrants and Rights Outstanding, Term (Year) | 2 years | ||
Stock Issued During Period, Warrants Exercised (in shares) | 62,293 | ||
Warrants to Purchase Common Stock [Member] | Senior Lenders [Member] | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 160,000 | ||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2 | ||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||
Warrants to Purchase Common Stock, Modification [Member] | Senior Lenders [Member] | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 10.2 | ||
Warrants and Rights Outstanding, Term (Year) | 3 years | ||
Class of Warrant or Right, Number of Additional Securities Called by Warrants or Rights (in shares) | 25,000 | ||
Warrants Issued to Subordinated Debt Holders [Member] | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 226,666 | ||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.01 | ||
Warrants and Rights Outstanding, Term (Year) | 2 years |
Note 8 - Warrants to Purchase_4
Note 8 - Warrants to Purchase Common Stock - Fair Value Assumptions (Details) | Dec. 31, 2023 $ / shares yr | Dec. 31, 2022 $ / shares yr |
Measurement Input, Expected Dividend Rate [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 0 | 0 |
Measurement Input, Risk Free Interest Rate [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 0.0385 | 0.0175 |
Measurement Input, Price Volatility [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 1.179 | 1.5141 |
Measurement Input, Expected Term [Member] | ||
Warrants and Rights Outstanding, Measurement Input | yr | 5 | 3 |
Measurement Input, Exercise Price [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 1.62 | 10.47 |
Measurement Input, Share Price [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 4.13 | 11.29 |
Fair Value per Warrant on Grant Date [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 3.92 | 9.68 |
Note 8 - Warrants to Purchase_5
Note 8 - Warrants to Purchase Common Stock - Schedule of Warrants or Rights (Details) - $ / shares shares in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Outstanding, warrants (in shares) | 355 | 55 | |
Outstanding, Weighted - Average Exercise Price (in dollars per share) | $ 15.92 | $ 2.59 | |
Outstanding, Average Remaining Term in Years (Year) | 5 years 9 months 7 days | 7 years 5 months 23 days | 4 years 11 months 12 days |
Granted, warrants (in shares) | 511 | 527 | |
Granted, Weighted - Average Exercise Price (in dollars per share) | $ 1.62 | $ 10.47 | |
Exercised, warrants (in shares) | (336) | (227) | |
Exercised, Weighted - Average Exercise Price (in dollars per share) | $ 0.83 | $ 0.01 | |
Outstanding, warrants (in shares) | 530 | 355 | |
Outstanding, Weighted - Average Exercise Price (in dollars per share) | $ 11.7 | $ 15.92 |
Note 9 - Stock-based Compensa_3
Note 9 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | |||||||
Aug. 26, 2021 | Apr. 25, 2019 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2020 | Dec. 31, 2021 | Jul. 01, 2021 | Mar. 31, 2016 | |
Share Price (in dollars per share) | $ 5.24 | $ 3.96 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) | 5,526,000 | 4,694,000 | ||||||
Share-Based Payment Arrangement, Expense | $ 7.7 | $ 6.4 | ||||||
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ 7.3 | |||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 6 months | |||||||
The 2019 Stock Plan [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) | 10 years | |||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | 4,558,621 | |||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage Increase in Shares Available for Issuance Based on Common stock Outstanding | 4% | |||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Measurement Input, Shares (in shares) | 2,541,823 | |||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 244,000 | |||||||
Share Price (in dollars per share) | $ 3.6 | $ 10.97 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) | 5,526,000 | 4,694,000 | 3,763,000 | |||||
The 2019 Stock Plan [Member] | Restricted Stock [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 89,000 | |||||||
The 2019 Stock Plan [Member] | Restricted Stock [Member] | Director [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 244,000 | 89,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value (in dollars per share) | $ 3.75 | $ 10.92 | ||||||
The 2019 Stock Plan [Member] | Share-Based Payment Arrangement, Employee [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares) | 1,300,000 | 1,300,000 | ||||||
The 2019 Stock Plan [Member] | Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Option [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) | 10 years | |||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 3 years | |||||||
Inducement Equity Plan Options [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | 100,000 | |||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) | 0 |
Note 9 - Stock-based Compensa_4
Note 9 - Stock-based Compensation - Schedule of Share-based Payment Award (Details) - $ / shares shares in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Balance, outstanding (in shares) | 4,694 | |
Balance, Weighted-Average Exercise Price (in dollars per share) | $ 4.63 | |
Balance, outstanding (in shares) | 5,526 | 4,694 |
Balance, Weighted-Average Exercise Price (in dollars per share) | $ 4.42 | $ 4.63 |
The 2019 Stock Plan [Member] | ||
Balance, Shares Available for Grant (in shares) | 65 | 42 |
Balance, outstanding (in shares) | 4,694 | 3,763 |
Balance, Weighted-Average Exercise Price (in dollars per share) | $ 4.63 | $ 2.29 |
Authorized, shares (in shares) | 1,644 | 1,338 |
Options Granted, shares (in shares) | (1,278) | (1,307) |
Options Granted, shares (in shares) | 1,278 | 1,307 |
Options Granted, Weighted-Average Exercise Price (in dollars per share) | $ 3.6 | $ 10.97 |
RSAs Granted, shares (in shares) | (244) | |
Exercised, outstanding (in shares) | (177) | (295) |
Exercised, Weighted-Average Exercise Price (in dollars per share) | $ 1.83 | $ 0.93 |
Forfeited/expired, shares available (in shares) | 269 | 81 |
Forfeited/expired, outstanding (in shares) | (269) | (81) |
Forfeited/expired, Weighted-Average Exercise Price (in dollars per share) | $ 5.93 | $ 11.63 |
Balance, Shares Available for Grant (in shares) | 456 | 65 |
Balance, outstanding (in shares) | 5,526 | 4,694 |
Balance, Weighted-Average Exercise Price (in dollars per share) | $ 4.42 | $ 4.63 |
The 2019 Stock Plan [Member] | Restricted Stock [Member] | ||
RSAs Granted, shares (in shares) | (89) |
Note 9 - Stock-Based Compensa_5
Note 9 - Stock-Based Compensation - Share-Based Compensation Arrangement by Share-Based Payment Award, Options Vested and Expected to Vest, Outstanding, and Exercisable (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 24 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | ||
Vested and Exercisable, number of shares (in shares) | 3,986 | 3,170 | |
Vested and Exercisable, weighted average exercise price (in dollars per share) | $ 3.58 | $ 2.46 | |
Vested and Exercisable, remaining contractual term (Year) | 6 years 5 months 19 days | 6 years 11 months 23 days | |
Vested and Exercisable, aggregate intrinsic value | [1] | $ 11,695 | $ 7,419 |
Unvested, number of share (in shares) | 1,540 | 1,524 | |
Unvested, weighted average exercise price (in dollars per share) | $ 6.55 | $ 9.13 | |
Unvested, remaining contractual term (Year) | 8 years 8 months 1 day | 8 years 9 months 21 days | |
Unvested, aggregate intrinsic value | [1] | $ 1,621 | $ 647 |
Number of shares (in shares) | 5,526 | 4,694 | |
Weighted average exercise price (in dollars per share) | $ 4.42 | $ 4.63 | |
Remaining contractual term (Year) | 7 years 14 days | 7 years 6 months 29 days | |
Aggregate intrinsic value | [1] | $ 13,316 | $ 8,066 |
[1]Intrinsic value based on the $5.24 and $3.96 closing price of Aemetis, Inc. common stock on December 31, 2023 and 2022 respectively, as reported on the NASDAQ Exchange. |
Note 9 - Stock-based Compensa_6
Note 9 - Stock-based Compensation - Fair Value Assumptions (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Market value per share on grant date (in dollars per share) | $ 5.24 | $ 3.96 |
The 2019 Stock Plan [Member] | ||
Dividend-yield | 0% | 0% |
Risk-free interest rate | 3.86% | 2.03% |
Expected volatility | 124.62% | 117.21% |
Expected life (years) (Year) | 7 years | 7 years |
Market value per share on grant date (in dollars per share) | $ 3.6 | $ 10.97 |
Fair value per share on grant date (in dollars per share) | $ 3.29 | $ 9.71 |
Note 10 - Agreements (Details T
Note 10 - Agreements (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Jul. 01, 2022 | |
Prepaid Expense, Current | $ 3,347 | $ 4,248 | |
Marketing Expense | 1,500 | 2,900 | |
Shipping and Handling Costs | 1,700 | 3,300 | |
Results of Operations, Transportation Costs | 3,300 | 5,300 | |
Forward Sales Commitments [Member] | |||
Other Commitment | 0 | ||
Operating Agreement with Gemini Edibles and Fats India Private Limited [Member] | |||
Debt Agreement, Maximum Borrowing Capacity | $ 12,700 | ||
Debt Instrument, Interest Rate, Stated Percentage | 12% | ||
Accounts Payable | 0 | 0 | |
J.D. Heiskell [Member] | |||
Prepaid Expense, Current | $ 0 | $ 2,400 |
Note 10 - Agreements - Schedule
Note 10 - Agreements - Schedule of Working Capital Agreement Activity (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenues | $ 186,717 | $ 256,513 |
Accounts payable | 32,132 | 26,168 |
J.D. Heiskell [Member] | ||
Accounts receivable | 1,073 | 0 |
Accounts payable | 1,207 | 27 |
Ethanol Sales [Member] | J.D. Heiskell [Member] | ||
Revenues | 77,359 | 0 |
Wet Distiller's Grains Sales [Member] | J.D. Heiskell [Member] | ||
Revenues | 21,963 | 50,930 |
CDO and CDS [Member] | J.D. Heiskell [Member] | ||
Revenues | 3,296 | 10,168 |
Corn Purchases [Member] | J.D. Heiskell [Member] | ||
Corn purchases | $ 83,128 | $ 191,401 |
Note 11 - Segment Information_2
Note 11 - Segment Information (Details Textual) gal in Millions | 3 Months Ended | 12 Months Ended | |
Sep. 30, 2023 | Dec. 31, 2023 gal | Dec. 31, 2022 | |
Number of Reportable Segments | 3 | ||
California Ethanol [Member] | |||
GallonPerYear (Gallon) | 65 | ||
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales [Member] | |||
Number of Major Customers | 1 | 1 | |
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales [Member] | Customer One [Member] | |||
Concentration Risk, Percentage | 100% | ||
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales, Wet Distillers Grain and Corn Oil Sales [Member] | |||
Number of Major Customers | 1 | ||
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales, Wet Distillers Grain and Corn Oil Sales [Member] | Customer One [Member] | |||
Concentration Risk, Percentage | 73% | ||
California Ethanol [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Ethanol Sales, Wet Distillers Grain and Corn Oil Sales [Member] | Customer Two [Member] | |||
Concentration Risk, Percentage | 26% | ||
India Biodiesel [Member] | |||
GallonPerYear (Gallon) | 60 | ||
India Biodiesel [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Biodiesel Sales [Member] | Customer One [Member] | |||
Concentration Risk, Percentage | 47% | 48% | |
India Biodiesel [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Biodiesel Sales [Member] | Customer Two [Member] | |||
Concentration Risk, Percentage | 25% | 29% | |
India Biodiesel [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Biodiesel Sales [Member] | Customer Three [Member] | |||
Concentration Risk, Percentage | 23% | 12% | |
California Dairy Renewable Natural Gas [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Sales of Biogas [Member] | |||
Number of Major Customers | 1 | ||
California Dairy Renewable Natural Gas [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Sales of Biogas [Member] | Customer One [Member] | |||
Concentration Risk, Percentage | 100% | ||
California Dairy Renewable Natural Gas [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | D3 RIN Credits [Member] | |||
Number of Major Customers | 1 | ||
California Dairy Renewable Natural Gas [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | D3 RIN Credits [Member] | Customer One [Member] | |||
Concentration Risk, Percentage | 98% |
Note 11 - Segment Information -
Note 11 - Segment Information - Schedule of Segment Reporting Information (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenues | $ 186,717 | $ 256,513 |
Gross profit (loss) | 2,017 | (5,535) |
Interest expense, including amortization of debt fees | 39,519 | 28,770 |
Accretion and other expenses of Series A preferred units | 25,313 | 9,888 |
Income tax expense (benefit) | (53,736) | 1,053 |
Capital expenditures | 33,119 | 39,157 |
Depreciation | 6,933 | 5,535 |
Total Assets | 243,406 | 207,114 |
Loss on debt extinguishment | 0 | 49,386 |
Intersegment Eliminations [Member] | ||
Revenues | 0 | 1,002 |
California Ethanol [Member] | ||
Revenues | 104,068 | 228,194 |
Gross profit (loss) | (6,602) | (13,017) |
Interest expense, including amortization of debt fees | 25,258 | 20,637 |
Accretion and other expenses of Series A preferred units | 0 | 0 |
Income tax expense (benefit) | 0 | 0 |
Capital expenditures | 5,695 | 8,399 |
Depreciation | 3,995 | 4,148 |
Total Assets | 67,991 | 66,794 |
Loss on debt extinguishment | 0 | |
California Ethanol [Member] | Intersegment Eliminations [Member] | ||
Revenues | 0 | 0 |
California Dairy Renewable Natural Gas [Member] | ||
Revenues | 5,455 | 208 |
Gross profit (loss) | (331) | (778) |
Interest expense, including amortization of debt fees | 2,809 | 742 |
Accretion and other expenses of Series A preferred units | 25,313 | 9,888 |
Income tax expense (benefit) | (55,159) | 6 |
Capital expenditures | 24,744 | 22,884 |
Depreciation | 2,116 | 615 |
Total Assets | 92,794 | 77,714 |
Loss on debt extinguishment | 49,386 | |
California Dairy Renewable Natural Gas [Member] | Intersegment Eliminations [Member] | ||
Revenues | 0 | 1,002 |
India Biodiesel [Member] | ||
Revenues | 77,194 | 28,111 |
Gross profit (loss) | 8,950 | 8,273 |
Interest expense, including amortization of debt fees | 447 | 119 |
Accretion and other expenses of Series A preferred units | 0 | 0 |
Income tax expense (benefit) | 1,416 | 1,040 |
Capital expenditures | 1,281 | 129 |
Depreciation | 576 | 650 |
Total Assets | 34,769 | 16,120 |
Loss on debt extinguishment | 0 | |
India Biodiesel [Member] | Intersegment Eliminations [Member] | ||
Revenues | 0 | 0 |
Other Segments [Member] | ||
Revenues | 0 | 0 |
Gross profit (loss) | 0 | (13) |
Interest expense, including amortization of debt fees | 11,005 | 7,272 |
Accretion and other expenses of Series A preferred units | 0 | 0 |
Income tax expense (benefit) | 7 | 7 |
Capital expenditures | 1,399 | 7,745 |
Depreciation | 246 | 122 |
Total Assets | 47,852 | 46,486 |
Loss on debt extinguishment | 0 | |
Other Segments [Member] | Intersegment Eliminations [Member] | ||
Revenues | $ 0 | $ 0 |
Note 11 - Segment Information_3
Note 11 - Segment Information - Reconciliation of Revenue from Segments to Consolidated (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenues | $ 186,717 | $ 256,513 |
Elimination of intersegment revenues | 0 | (1,002) |
Operating Segments [Member] | ||
Revenues | $ 186,717 | $ 257,515 |
Note 12 - Related Party Trans_2
Note 12 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Share-Based Payment Arrangement, Expense | $ 7,700 | $ 6,400 |
Mr. McAfee [Member] | ||
Accrued Liabilities, Current | 175 | |
Various Board Members [Member] | ||
Share-Based Payment Arrangement, Expense | 400 | 400 |
Employment Agreements and Expense Reimbursements [Member] | Mr. McAfee [Member] | ||
Related Party Transaction, Amounts of Transaction | 400 | |
Accrued Liabilities | 400 | |
One-time Guarantee Fee [Member] | Mr. McAfee [Member] | ||
Related Party Transaction, Amounts of Transaction | 350 | |
Board Compensation Fees [Member] | Various Board Members [Member] | ||
Related Party Transaction, Amounts of Transaction | $ 300 | $ 300 |
Note 13 - Income Tax (Details T
Note 13 - Income Tax (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Deferred Tax Liabilities, Net, Total | $ 735 | $ 810 |
Undistributed Earnings of Foreign Subsidiaries | 1,300 | $ 2,500 |
Alcohol and Cellulosic Biofuel Credit Carryforward [Member] | ||
Tax Credit Carryforward, Amount | 1,500 | |
Carbon Oxide Sequestration Credit Carryforward [Member] | ||
Tax Credit Carryforward, Amount | 6,700 | |
Domestic Tax Authority [Member] | ||
Operating Loss Carryforwards | $ 253,000 | |
Domestic Tax Authority [Member] | Minimum [Member] | ||
Operating Loss Carryforwards, Expiration Date | Dec. 31, 2027 | |
Domestic Tax Authority [Member] | Maximum [Member] | ||
Operating Loss Carryforwards, Expiration Date | Dec. 31, 2043 | |
State and Local Jurisdiction [Member] | ||
Operating Loss Carryforwards | $ 336,000 | |
State and Local Jurisdiction [Member] | Minimum [Member] | ||
Operating Loss Carryforwards, Expiration Date | Dec. 31, 2027 | |
State and Local Jurisdiction [Member] | Maximum [Member] | ||
Operating Loss Carryforwards, Expiration Date | Dec. 31, 2042 |
Note 13 - Income Tax - Schedule
Note 13 - Income Tax - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Federal tax expense, current | $ (55,164) | $ 0 |
State and Local tax expense, current | 13 | 13 |
Foreign tax expense, current | 1,489 | 230 |
Total tax expense, current | (53,662) | 243 |
Federal tax expense, deferred | 0 | 0 |
State and Local tax expense, deferred | 0 | 0 |
Foreign tax expense, deferred | (74) | 810 |
Income tax (benefit) expense | $ (53,736) | $ 1,053 |
Note 13 - Income Tax - Schedu_2
Note 13 - Income Tax - Schedule of Income Before Income Tax, Domestic and Foreign (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
United States | $ (107,191) | $ (112,959) |
Foreign | 7,035 | 6,254 |
Loss before income taxes | $ (100,156) | $ (106,705) |
Note 13 - Income Tax - Schedu_3
Note 13 - Income Tax - Schedule of Effective Tax Rate Reconciliation (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Income tax benefit at the federal statutory rate | $ (21,033) | $ (22,408) |
State tax benefit | (999) | (496) |
Sale of tax credits | (55,164) | 0 |
Foreign tax differential | 11 | 168 |
Stock-based compensation | 2,048 | 295 |
Interest Expense | 92 | 58 |
GILTI Inclusion | 0 | 1,126 |
Prior year true-ups | (18,031) | 55 |
Non-includible US Entities | 0 | 13,499 |
Other | 67 | 46 |
Credits | (869) | (2,373) |
Valuation Allowance | 40,142 | 11,083 |
Income tax (benefit) expense | $ (53,736) | $ 1,053 |
Effective Tax Rate | 53.65% | (0.99%) |
Note 13 - Income Tax - Schedu_4
Note 13 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Organizational Costs, Start-up and Intangible Assets | $ 34,217 | $ 2,309 |
Stock Based Compensation | 1,239 | 1,842 |
NOLs, Unabsorbed Depreciation and R&D Credits C/F's | 67,621 | 68,201 |
Interest expense carryover | 29,066 | 22,374 |
Accrued Expenses | 2,249 | 2,001 |
Operating Lease Liability | 1,282 | 1,512 |
Other, net | 248 | 113 |
Total Deferred Tax Assets | 144,118 | 105,679 |
Valuation Allowance | (135,354) | (95,214) |
Net Deferred Tax Assets | 8,764 | 10,465 |
Right of Use Asset | (1,230) | (1,477) |
Property, Plant & Equipment | (8,266) | (9,788) |
Other, net | (3) | (10) |
Total Deferred Tax Liabilities | (9,499) | (11,275) |
Net Deferred Tax Liabilities | (735) | (810) |
Ethanol Credits [Member] | ||
Deffered tax assets, tax credit carryforwards | 1,500 | 1,500 |
Carbon Oxide Sequestration Credit Carryforward [Member] | ||
Deffered tax assets, tax credit carryforwards | $ 6,696 | $ 5,827 |
Note 13 - Income Tax - Open Tax
Note 13 - Income Tax - Open Tax Years by Major Tax Jurisdiction (Details) | 12 Months Ended |
Dec. 31, 2023 | |
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | |
Open tax year | 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 |
State and Local Jurisdiction [Member] | |
Open tax year | 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 |
Foreign Tax Authority [Member] | Ministry of Finance, India [Member] | |
Open tax year | 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 |
Foreign Tax Authority [Member] | Mauritius Revenue Authority [Member] | |
Open tax year | 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 |
Note 14 - Parent Company Fina_3
Note 14 - Parent Company Financial Statements (Unaudited) - Condensed Balance Sheets (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Cash and cash equivalents | $ 2,667 | $ 4,313 |
Prepaid expenses | 3,347 | 4,248 |
Other current assets | 3,462 | 3,653 |
Total current assets | 36,400 | 18,136 |
Property, plant and equipment, net | 195,108 | 180,441 |
Total Assets | 243,406 | 207,114 |
Accounts payable | 32,132 | 26,168 |
Other current liabilities | 10,302 | 8,474 |
Total current liabilities | 84,389 | 88,281 |
Operating lease liability | 2,189 | 2,527 |
Total long term liabilities | 375,994 | 320,687 |
Common stock | 41 | 36 |
Additional paid-in capital | 264,058 | 232,546 |
Accumulated deficit | (475,405) | (428,985) |
Accumulated other comprehensive loss | (5,671) | (5,452) |
Total stockholders' deficit | (216,977) | (201,854) |
Total liabilities & stockholders' deficit | 243,406 | 207,114 |
Convertible Series B Preferred Stock Subject to Mandatory Redemption [Member] | ||
Mandatorily redeemable Series B convertible preferred | 4,521 | 4,082 |
Parent Company [Member] | ||
Cash and cash equivalents | 1,454 | 286 |
Receivables due from subsidiaries | 110,083 | 98,780 |
Prepaid expenses | 437 | 611 |
Other current assets | 12 | 7 |
Total current assets | 111,986 | 99,684 |
Investment in subsidiary, net of advances | 14,499 | 8,106 |
Property, plant and equipment, net | 149 | 135 |
Other assets | 2,096 | 2,377 |
Total Assets | 128,730 | 110,302 |
Accounts payable | 3,633 | 2,934 |
Other current liabilities | 5,031 | 4,269 |
Total current liabilities | 13,185 | 11,285 |
Operating lease liability | 1,716 | 2,047 |
Subsidiary obligation in excess of investment | 330,806 | 298,824 |
Total long term liabilities | 332,522 | 300,871 |
Common stock | 41 | 36 |
Additional paid-in capital | 264,058 | 232,546 |
Accumulated deficit | (475,405) | (428,985) |
Accumulated other comprehensive loss | (5,671) | (5,452) |
Total stockholders' deficit | (216,977) | (201,854) |
Total liabilities & stockholders' deficit | 128,730 | 110,302 |
Parent Company [Member] | Series B Preferred Stock [Member] | ||
Series B Preferred convertible stock | 0 | 1 |
Parent Company [Member] | Convertible Series B Preferred Stock Subject to Mandatory Redemption [Member] | ||
Mandatorily redeemable Series B convertible preferred | 4,521 | 4,082 |
Parent Company [Member] | Aemetis Property Keyes, Inc. [Member] | ||
Investment in subsidiary, net of advances | 1,556 | 1,274 |
Parent Company [Member] | Aemetis International, Inc. [Member] | ||
Investment in subsidiary, net of advances | 12,059 | 6,659 |
Parent Company [Member] | Aemetis Advanced Products Riverbank, Inc. [Member] | ||
Investment in subsidiary, net of advances | 638 | 173 |
Parent Company [Member] | AE Advanced Products Keyes, Inc. [Member] | ||
Investment in subsidiary, net of advances | 246 | 0 |
Subsidiary obligation in excess of investment | 0 | 270 |
Parent Company [Member] | AE Advanced Fuels, Inc. [Member] | ||
Subsidiary obligation in excess of investment | 220,571 | 177,856 |
Parent Company [Member] | Aemetis Americas, Inc. [Member] | ||
Subsidiary obligation in excess of investment | 202 | 205 |
Parent Company [Member] | Aemetis Biofuels, Inc. [Member] | ||
Subsidiary obligation in excess of investment | 2,721 | 2,738 |
Parent Company [Member] | Aemetis Technologies, Inc. [Member] | ||
Subsidiary obligation in excess of investment | 4,868 | 4,716 |
Parent Company [Member] | Aemetis Health Products, Inc. [Member] | ||
Subsidiary obligation in excess of investment | 2,084 | 2,076 |
Parent Company [Member] | Goodland Advanced Fuels, Inc. [Member] | ||
Subsidiary obligation in excess of investment | 22,982 | 16,869 |
Parent Company [Member] | Aemetis Biogas LLC [Member] | ||
Subsidiary obligation in excess of investment | 70,471 | 91,292 |
Parent Company [Member] | Aemetis Carbon Capture, Inc. [Member] | ||
Subsidiary obligation in excess of investment | 5,895 | 2,323 |
Parent Company [Member] | Aemetis Properties Riverbank, Inc. [Member] | ||
Subsidiary obligation in excess of investment | $ 1,012 | $ 479 |
Note 14 - Parent Company Fina_4
Note 14 - Parent Company Financial Statements (Unaudited) - Condensed Statements of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Selling, general and administrative expenses | $ 39,266 | $ 28,686 |
Operating loss | (37,401) | (34,401) |
Interest expense | 39,519 | 28,770 |
Debt related fees and amortization expense | 6,524 | 7,363 |
Other income | (2,077) | (14,340) |
Income tax expense (benefit) | (53,736) | 1,053 |
Net loss | (46,420) | (107,758) |
Comprehensive loss | (46,639) | (108,860) |
Parent Company [Member] | ||
Equity in subsidiary losses | (25,370) | (91,561) |
Selling, general and administrative expenses | 19,218 | 15,203 |
Operating loss | (44,588) | (106,764) |
Interest expense | 1,073 | 806 |
Debt related fees and amortization expense | 781 | 1,581 |
Other income | (30) | (1,400) |
Loss before income taxes | (46,412) | (107,751) |
Income tax expense (benefit) | 8 | 7 |
Net loss | (46,420) | (107,758) |
Foreign currency translation adjustment | (219) | (1,102) |
Comprehensive loss | $ (46,639) | $ (108,860) |
Note 14 - Parent Company Fina_5
Note 14 - Parent Company Financial Statements (Unaudited) - Condensed Statements of Cash Flows (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Jun. 30, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Net loss | $ (46,420) | $ (107,758) | |
Share-based compensation | 7,660 | 6,410 | |
Depreciation | 6,933 | 5,535 | |
Debt related fees and amortization expense | 6,524 | 7,363 | |
Gain on litigation | $ (1,400) | 0 | (1,400) |
Warrants issued for working capital agreement | 409 | 0 | |
Prepaid expenses | (1,838) | (1,777) | |
Accounts payable | 13,726 | 2,183 | |
Accrued interest expense | 23,558 | 15,501 | |
Other liabilities | (1,757) | (10,125) | |
Net cash provided by (used in) operating activities | 13,825 | (22,866) | |
Capital expenditures | (33,119) | (39,157) | |
Net cash used in investing activities | (23,687) | (31,306) | |
Proceeds from the exercise of stock options | 133 | 206 | |
Proceeds from issuance of common stock in equity offering | 21,718 | 11,987 | |
Net cash provided by financing activities | 9,094 | 53,633 | |
Net change in cash and cash equivalents for period | (719) | (752) | |
Cash, cash equivalents, and restricted cash at beginning of period | 6,999 | 7,751 | |
Cash, cash equivalents, and restricted cash at end of period | 6,280 | 6,999 | |
Income taxes paid | 20 | 10 | |
Fair value of warrants issued to subordinated debt holders | 1,278 | 1,939 | |
Fair value of stock issued to a related party for guarantee fees | 0 | 2,012 | |
Fair value of warrants issued to lender for debt issuance costs | 318 | 3,158 | |
Fair value of stock issued to lender | 0 | 1,335 | |
Parent Company [Member] | |||
Net loss | (46,420) | (107,758) | |
Share-based compensation | 7,660 | 6,410 | |
Depreciation | 51 | 29 | |
Debt related fees and amortization expense | 782 | 1,776 | |
Subsidiary portion of net losses | 25,370 | 91,561 | |
Gain on litigation | 0 | (1,400) | |
Warrants issued for working capital agreement | 409 | 0 | |
Prepaid expenses | 608 | (111) | |
Accounts payable | 699 | (90) | |
Accrued interest expense | 785 | 778 | |
Other liabilities | 85 | (4,625) | |
Other assets | (276) | (207) | |
Net cash provided by (used in) operating activities | (10,911) | (13,001) | |
Capital expenditures | (65) | (128) | |
Subsidiary advances, net | (9,707) | 1,222 | |
Net cash used in investing activities | (9,772) | 1,094 | |
Proceeds from the exercise of stock options | 133 | 206 | |
Proceeds from issuance of common stock in equity offering | 21,718 | 11,987 | |
Net cash provided by financing activities | 21,851 | 12,193 | |
Net change in cash and cash equivalents for period | 1,168 | 286 | |
Cash, cash equivalents, and restricted cash at beginning of period | 286 | 0 | |
Cash, cash equivalents, and restricted cash at end of period | 1,454 | 286 | |
Income taxes paid | 7 | 7 | |
Fair value of warrants issued to subordinated debt holders | 1,278 | 1,939 | |
Fair value of stock issued to a related party for guarantee fees | 0 | 2,012 | |
Fair value of warrants issued for capital expenditures | 318 | 0 | |
Fair value of warrants issued to lender for debt issuance costs | 0 | 3,158 | |
Fair value of stock issued to lender | $ 0 | $ 1,335 |
Note 15 - Subsequent Events (De
Note 15 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | Feb. 08, 2023 | Mar. 06, 2020 | Mar. 25, 2024 | Mar. 22, 2024 | Jan. 01, 2024 | Dec. 31, 2023 | Jul. 01, 2023 | Jan. 01, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Mar. 14, 2021 | Jan. 09, 2012 | Jan. 06, 2012 |
Warrants and Rights Outstanding, Term (Year) | 5 years 9 months 7 days | 7 years 5 months 23 days | 4 years 11 months 12 days | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 11.7 | $ 15.92 | $ 2.59 | ||||||||||
Line of Credit [Member] | Required Credit Agreement to Satisfy Units Redemption Obligation [Member] | |||||||||||||
Debt Instrument, Term (Year) | 12 months | ||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 111,000 | ||||||||||||
PUPA Fifth Amendment [Member] | |||||||||||||
Preferred Units Issued Value | $ 111,000 | ||||||||||||
AAFK [Member] | Warrants in Connection With Subordinated Notes [Member] | |||||||||||||
Warrants and Rights Outstanding, Term (Year) | 2 years | 2 years | 2 years | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||
Subsequent Event [Member] | AAFK [Member] | Warrants in Connection With Subordinated Notes [Member] | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 113 | ||||||||||||
Warrants and Rights Outstanding, Term (Year) | 2 years | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.01 | ||||||||||||
Subordinated Notes [Member] | AAFK [Member] | |||||||||||||
Debt Instrument, Fee Amount | $ 2,500 | $ 900 | |||||||||||
Subordinated Notes [Member] | Subsequent Event [Member] | |||||||||||||
Equity Financing | $ 25,000 | ||||||||||||
Subordinated Notes 1 [Member] | AAFK [Member] | |||||||||||||
Debt Instrument, Cash Extension Fee | $ 90 | $ 90 | |||||||||||
Subordinated Notes 1 [Member] | Subsequent Event [Member] | AAFK [Member] | |||||||||||||
Debt Instrument, Cash Extension Fee | 90 | ||||||||||||
Subordinated Notes 2 [Member] | AAFK [Member] | |||||||||||||
Debt Instrument, Cash Extension Fee | $ 250 | $ 250 | |||||||||||
Subordinated Notes 2 [Member] | Subsequent Event [Member] | AAFK [Member] | |||||||||||||
Debt Instrument, Cash Extension Fee | $ 250 | ||||||||||||
Reserve Liquidity Facility [Member] | Third Eye Capital [Member] | |||||||||||||
Debt Instrument, Term (Year) | 1 year | ||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 70,000 | ||||||||||||
Reserve Liquidity Facility [Member] | Subsequent Event [Member] | Third Eye Capital [Member] | |||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 85,000 | $ 85,000 | |||||||||||
Debt Instrument, Fee Amount | 500 | ||||||||||||
Amendment No 28 [Member] | Subsequent Event [Member] | Third Eye Capital [Member] | |||||||||||||
Debt Instrument, Fee Amount | $ 100 |
Note 16 - Liquidity (Details Te
Note 16 - Liquidity (Details Textual) - Third Eye Capital [Member] - Reserve Liquidity Facility [Member] - USD ($) $ in Millions | Mar. 25, 2024 | Mar. 22, 2024 | Mar. 14, 2021 |
Line of Credit Facility, Maximum Borrowing Capacity | $ 70 | ||
Subsequent Event [Member] | |||
Line of Credit Facility, Maximum Borrowing Capacity | $ 85 | $ 85 |